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Alzheimer’s disease is a neurodegenerative disease of the brain and the leading cause of 
dementia globally. Severe cognitive and short term memory deficits are commonly associated 
with this disease. The pathology is characterised by two molecular hallmarks that manifest in 
brain tissue, which are intercellular plaques composed of β-amyloid, and intracellular protein 
aggregates known as neurofibrillary tangles (NFTs) composed of phosphorylated Tau, a 
microtubule (MT) associated protein (MAP). Under homeostatic conditions Tau facilitates the 
dynamic polymerisation of the microtubule network, which acts as part of the cytoskeleton and 
platform for vesicular transport. Tau is generally phosphorylated to modulate its binding affinity 
to the network. However, under pathological conditions it becomes hyperphosphorylated, 
leading to dissociation from the MT. Dissociated Tau is thought to form NFT aggregates, which 
causes the MT to become susceptible to cleavage by the severing proteins, Katanin p60 and 
Spastin. However, it has not been determined when this process occurs in disease 
progression and whether it is indeed a confounding factor leading to the onset of neuronal cell 
death. Moreover, although dysfunction of the autophagic lysosomal pathway, an inherent 
proteolytic process for long-lived proteins and organelles, has been shown to be implicated in 
the onset of protein aggregation, its role in the context of MT dysfunction remains unclear. 
Aims and Methods 
The aims of this study were to assess microtubulin and Tau dynamics in an in vitro model of 
autophagic dysfunction that is similar to the Alzheimer’s disease pathology. It was 
hypothesized that a disruption in the autophagy process would lead to maladaptive changes 
in the microtubulin and Tau dynamics prior to the onset of cell death. 
GT1-7 neuronal cells were cultured under standard conditions and treated with Chloroquine 
diphosphate (CQ), a lysosome deacidifying agent, to induce an autophagic dysfunctional 
state. Two time points of exposure to CQ were established using a WST-1 assay to assess 
the molecular changes occurring prior to and during the onset of cell death. Western blot 
analysis was utilised to quantify protein levels of acetylated α-tubulin, Tau, pTau, Katanin p60 
and Spastin in response to CQ-induced autophagy dysfunction. Furthermore, cells were 
transfected with a GFP-Tau DNA construct, using the Neon® transfection system. Additionally, 
cells were fixed and stained post-transfection with fluorescent Alexa® Fluor secondary 
antibodies against primary antibodies recognising acetylated α-tubulin, pTau, Katanin p60 and 
Spastin. Fluorescent microscopy analysis was performed using Super Resolution Structured 
Illumination Microscopy (SR-SIM), Stochastic Optical Reconstruction Microscopy (STORM), 





Correlative Light and Electron Microscopy (CLEM) and confocal microscopy techniques on 
the LSM-780 Elyra PS.1 system to assess protein localisation in response to CQ treatment. 
Moreover, co-localisation was assessed between acetylated α-tubulin and Tau, pTau, Spastin 
and Katanin p60 respectively. 
Results 
Fluorescent microscopy analysis revealed that CQ-induced autophagy dysfunction caused 
acetylated α-tubulin protein structure to become progressively impacted, which manifested as 
breakages in the network. Tau protein levels decreased non-significantly, but fluorescent 
microscopy revealed the formation intracellular Tau aggregates. In addition, Tau co-localised 
with acetylated α-tubulin under control conditions and remained co-localised in response to 
CQ treatment. Phosphorylated Tau protein levels did increase non-significantly, but 
fluorescent microscopy revealed no aggregate formation. Katanin p60 protein levels 
significantly increased, however, the protein did not co-localise with acetylated α-tubulin under 
control conditions or in response to CQ-induced autophagy dysfunction. Spastin protein levels 
increased non-significantly, however, Spastin co-localised with acetylated α-tubulin under 
control conditions, which significantly increased in response to autophagy dysfunction. 
Discussion and Conclusion 
Our results indicate that CQ-induced autophagy dysfunction causes Tau aggregation, but no 
dissociation from the microtubule network. Furthermore, the microtubulin network becomes 
unstable, despite its continuous association with Tau, which may be caused by increased 
Spastin-mediated severing. 
To conclude, the data clearly demonstrate that these pathological perturbations occur prior to 
the onset of cell death, which not only highlights novel therapeutic targets, but also the lack of 
optimal timing in the therapeutic interventions utilised in Alzheimer’s disease treatment.   








Alzheimer’s siekte is ‘n neurodegeneratiewe siekte van die brein en die hoofoorsaak van 
demensie ter wêreld. Hewige kognitiewe en korttermyngeheue gebreke word algemeen 
geassosiëer met hierdie siekte. Die patologie word gekenmerk deur twee molekulêre 
kenmerke wat manifesteer in die breinweefsel. Dit sluit in intersellulêre plaakvorming wat 
bestaan uit amiloïed-β, en intrasellulêre aggregate, ook bekend as neurofibrillêre knope 
(NFK), wat uit Tau, ’n mikrotubulêre (MT) geassosiëerde proteïn (MAP) bestaan. Onder 
homeostatiese toestande fasiliteer Tau die dinamiese polimerisasie van die mikrotubulêre 
netwerk, wat dien as deel van die sitoskelet, en ook as ’n platform vir vesikulêre vervoer 
funksioneer. Tau is normaalweg gefosforileer om die bindingsaffiniteit vir die mikrotubulêre 
netwerk te moduleer. Nieteenstande, onder patologiese toestande word Tau 
gehiperfosforileer wat veroorsaak dat dit van die mikrotubulêre netwerk dissosiëer. 
Gedissosieerde Tau vorm vermoedelik neurofibrillêre knope, wat veroorsaak dat die 
mikrotubulêre netwerk vatbaar is vir degradasie deur die proteïne, katanin p60 en spastin. 
Nieteenstaande, is dit nog nie vasgestel waneer hierdie proses in die siekte progressie plaas 
vind nie, en of dit ’n bepalende faktor is wat lei tot die aanslag van neuronale seldood. Hoewel 
disfunksionering van die autofagiese lisosoomsisteem, ’n proteolitiese proses vir verouderde 
en beskadigde proteïne en organelle, geimpliseerd is in die aanslag van die vervorming van 
proteïn aggregate, is dit in die konteks van mikrotubulêre netwerk destabilisasie steeds 
onduidelik. 
Doel en Metodes 
Die doel van hierdie studie was dus om die dinamika van Tau en die mikrotubulêre netwerk in 
’n in vitro model van autofagiese dusfunksionering, wat soortgelyk is aan die Alzheimer’s 
siekte patologie, te ondersoek. Die hipotese wat gestel is, is dat ’n ontwrigting in die 
outofagiese proses tot wanaangepaste veranderinge in die dinamika van Tau en die 
mikrotubulêre netwerk voor die aanslag van seldood sal aanleiding gee. 
GT1-7 neuronale selle was deur middel van selkultuur geweek onder standaardtoestande met 
’n lisosomiese onversuringsmiddel, chlorokiendifosfaat (CQ) behandel, om ’n outofagiese 
disfunksionele toestand te veroorsaak. Twee CQ blootstellingsperiodes was vasgestel met ’n 
WST-1 toets om molekulêre veranderinge, voor en gedurende die aanvang van seldood, te 
ondersoek. Western blot analiese is gebruik om die proteïnvlakke van geasetileerde α-
tubulien, Tau, pTau, katanin p60 en spastin in reaksie op CQ-geïnduseerde autofagiese 
disfunksie, te kwantifiseer. Selle was getransfekteer met ’n GFP-Tau DNS plasmied met die 





Neon® transfekteringsstelsel. Verder, was selle chemies gepreseveer na transfektering en met 
fluoresserende Alexa® Fluor sekondêre teenliggaampies teen die primêre teenliggaampies 
wat geasetileerde α-tubulien, pTau, katanin p60 en spastin erken, gekleur. Fluoressensie 
mikroskopie is gebruik met behulp van Super Resolusie Gestruktureerde Verligtings 
Mikroskopie (SR-SIM), Stogastiese Optiese Rekonstruksie Mikroskopie (STORM), 
Korrelatiewe Lig en Elektron Mikroskopie (CLEM), en konfokale mikroskopiese tegnieke op 
die LSM-780 Elyra PS.1 stelsel, om proteïenlokalisering te evalueer in reaksie op CQ 
behandeling. Verder, was ko-lokalisering tussen geasetileerde α-tubulien en pTau, katanin 
p60 en spastin onderskeidelik geëvalueer. 
Resultate 
Fluoressensie mikroskopie analiese het gewys dat CQ-geïnduseerde outofagiese disfunksie 
’n progressiewe impak op die geasetileerde α-tubulien struktuur gehad het, wat gemanifesteer 
as gebreke in die netwerk. Tau proteïenvlakke het nie betekenisvol afgeneem nie. 
Fluoressensie mikroskopie analiese het ook gewys dat Tau aggregate in reaksie op CQ 
behandling gevorm het. Benewens, het Tau geko-lokaliseer met geasetileerde α-tubulien 
onder onbehandelde toestande, en só gebly tydens outofagiese disfunksie. Gefosforileerde 
Tau proteïenvlakke het nie betekenisvol toegeneem nie, en geen proteïenaggregate het 
gevorm nie. Katanin p60 proteïenvlakke het beduidenlik toegneem, maar het nie met die 
geasetileerde α-tubulien die in onbehandelde toestande òf gedurende outofagiese disfunksie 
geko-lokaliseer nie. Spastienproteïenvlakke het nie betekensvol toegneem nie. Spastien het 
geko-lokaliseer met die geasetileerde α-tubulien onder onbehandelde toestande, en het 
progressief en beduidenlik geko-lokaliseer tydens outofagiese disfunksie. 
Bespreking en gevolgtrekking 
Ons resultate toon dat CQ-geïnduseerde outofagiese disfunksie veroorsaak dat Tau 
aggregate vorm, maar nie van die mikrotubulêre netwerk dissosiëer nie. Verder, word die 
mikrotubulêre netwerk onstabiel ten spyte van die gedurende assosiëering met Tau, wat mag 
aandui dat daar ’n toename in spastien bemiddelde degradasie van die netwerk is. 
Opsommend demonstreer hierdie data dat die patologiese versteurings voor die aanslag van 
seldood plaasvind. Dit beklemtoon nie net moontlike nuwe terapeutiese teikens nie, maar ook 
die gebrek aan optimale tydsberekening in terapeutiese intervensies wat gebruik word in 
Alzheimer’s siekte behandeling.  
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LOAD    Late Onset Alzheimer’s disease 
LTP    Long Term Potentiation 
MAP    Microtubule associated protein 
MAPT    Microtubule associated protein Tau gene 
MARK    Microtubule Affinity Regulating Kinase 
MEFs    Mouse Embryonic Fibroblasts 
Mfn1/2   Mitofusin1/2 
MOA    Monoamine Oxidase α 
MOC    Mander’s Overlap Co-efficient 
mRNA   messenger ribonucleic acid 
MSEs    Microtubule Severing Enzymes 
mtDNA   mitochondrial deoxyribonucleic acid 
MTOC   Microtubule organising centre 
mTORC1   mammalian Target Of Rapamycin Complex 1 
NFTs    Neurofibrillary Tangles 
NMDA   N-methyl-D-aspartate 
NMDAR   N-methyl-D-aspartate Receptor 
OPA1    Optic Atrophy 1 
PAGE    Polyacrylamide Gel Electrophoresis 
PARP    Poly (ADP-ribose) Polymerase 
PE    Phosphatidylethanolamine 
PI3K CIII   Phosphatidylinositol 3-kinase complex 3 
PI3K    Phosphatidylinositol 3-Kinase 
PI3P    Phosphatidyl-Inositol-3-Phosphate 





PINK1    PTEN-induced putative kinase 1 
PSEN-1/-2   Presenilin-1 and -2 
PTEN    Phosphate Tensin Homologue 
PVDF    Polyvinylidine fluoride 
RE    Recycling Endosome 
RIPA    Radio-immunoprecipitation 
ROS    Reactive Oxygen Species 
Rpn    Regulatory particle non-ATPase 
SDS    Sodium Dodecyl Sulphate 
SDS-PAGE   Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
SEM    Scanning Electron Microscopy 
SFs    Straight filaments 
SNX    Sorting Nexin 
SQSTM1   Sequestosome 1 (p62) 
SR-SIM   Super-Resolution Structured Illumination Microscopy 
STORM   Stochastic Optical Reconstruction Microscopy 
TCA    Tricarboxylic acid cycle 
TGN    Trans-Golgi-Network 
TNFR1   Tumour Necrosis Factor-α Receptor 1 
TNF-α    Tumour Necrosis Factor – α 
TRADD   Tumour Necrosis Factor-α Death Domain 
TTLL6    Tubulin Tyrosine-Like Ligase 6 
Ub    Ubiquitin 
ULK    unc-51 like autophagy activating kinase 1 
UPS    Ubiquitin Proteasome System 
UV    Ultra Violet 
v-ATPase   Vacuole- ATPase 
WHO    World Health Organization  
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Chapter 1: Literature Review 
1.1 Introduction  
Alzheimer’s disease is a progressive neurodegenerative disease of the brain and the leading 
cause of dementia globally. It is characterised by progressive synaptic dysfunction and 
neuronal loss that manifests symptomatically as behavioural changes, cognitive decline and 
memory deficits (Nixon & Yang 2011; Musiek & Holtzman 2015). The disease is presently 
incurable and current treatment modalities are aimed at ameliorating symptoms and slowing 
down progression (Kumar et al. 2015; Rafii & Aisen 2015). The available treatments and 
available care place a large burden on the global economy with estimated cost of care to be 
approximately $604 billion annually (Prince et al. 2015). 
The latest estimation of the current global prevalence is approximately 44 million, with women 
being affected more (Carter et al. 2012; Olayinka & Mbuyi 2014). A paucity exists on the exact 
prevalence of AD in South Africa (Lekoubou et al. 2014). In the South African context, it was 
found that up to 79% of patients were being cared for by family members, many of which had 
given up employment to do so (Kalula et al. 2010). In addition, more than 40% of the South 
African population live within remote rural areas, which has a negative impact on the treatment 
and diagnosis of dementia (de Jager et al. 2015). Additionally, the global prevalence is 
expected to increase to 135 million people by the year 2050 and will inexorably shift to 
developing states such as South Africa, which may place further strain on the growing 
economy (Prince et al. 2015). 
The disease pathophysiology is multifactorial and highly complex, having both genetic and 
possible environmental causes (Reitz & Mayeux 2014; Musiek & Holtzman 2015). Multiple co-
morbidities, such as diabetes and vascular damage, are associated with an increased risk for 
developing AD and dementia related disorders (Reitz & Mayeux 2014). Since the disease 
predominantly affects the aged population, advanced age remains the highest risk (Reitz & 
Mayeux 2014). 
There are two subsets of the disease. The first being the least common early-onset Familial 
Alzheimer’s disease (FAD), with strong genetic links; and the second, sporadic late-onset 
Alzheimer’s disease (LOAD), which has no clear cause (Reitz & Mayeux 2014; Musiek & 
Holtzman 2015). Current estimations suggest that LOAD sufferers make up 95% of the total 
affected global population (Reitz & Mayeux 2014). 
AD has an expansive prodromal stage which, in most cases, precedes symptom onset by at 
least 20 - 30 years (Caselli & Reiman 2012; Cash et al. 2013). In this time, pathological 
molecular changes occur within brain tissue. These changes present mainly as two physical 





hallmarks which manifest as a result of perturbations in cellular proteostasis - the appropriate 
balance of protein synthesis, processing, and turnover in the cell – although the precise 
mechanisms often remain unclear (Ballatore et al. 2007; Lee et al. 2013). The first molecular 
hallmark is the manifestation of extracellular aggregates, commonly known as senile plaques, 
which are composed of the membrane associated protein β-amyloid (Musiek & Holtzman 
2015). The second is the appearance of intracellular aggregates, known as neurofibrillary 
tangles (NFTs), which are mainly composed of the hyperphosphorylated microtubule 
associated protein (MAP) Tau (Nixon & Yang 2011). Tau stabilises the microtubule network, 
which is a crucial part of the cytoskeleton – serving as a track for organelle and vesicular 
transport (Avila et al. 2004). Under physiological conditions Tau is phosphorylated to modulate 
its binding affinity to the microtubule. However, under pathological conditions, Tau becomes 
hyperphosphorylated and prone to aggregation, causing dissociation from the microtubule 
(Lee et al. 2013). Consequently, the dissociation of Tau leads to microtubule instability and 
fragmentation – a process that still remains largely unknown. Multiple lines of evidence have 
shown that amyloid pathology is the driving force responsible for Tau hyperphosphorylation, 
but the exact mechanism is not fully understood (Jean & Baas 2013). Furthermore, AD 
affected neurons exhibit a progressive loss in axonal branching and size as a result of the 
microtubule loss. In fact, the microtubule network is capable of being cleaved by specialised 
microtubule severing enzymes (MSEs) (Jean & Baas 2013). Spastin and Katanin are the most 
commonly studied amongst the MSEs in neurons (Zhang et al. 2007). Current evidence 
suggest that the Tau protein may participate in the regulation of these enzyme activities by 
decreasing the availability of exposed microtubule surface area needed for optimal MSE 
binding (Baas & Qiang 2005). 
Recently, proteolytic processes aiding in the clearance of protein aggregates have also been 
implicated in the disease pathophysiology. These proteolytic pathways include the ubiquitin-
proteasome system (UPS), the autophagy-lysosomal pathway (ALP) and the endocytic-
lysosomal pathway (ELP). Dysregulation of these systems has been well documented in AD 
pathophysiology and evidence suggests that this occurs prior to the appearance of Aβ and 
Tau pathology, suggesting a potential causality (Nixon & Yang 2011; Lee et al. 2013; Perez 
et al. 2015; Cataldo et al. 2000). Dysregulation of the ALP/ELP has received particular 
attention as they depend on the microtubule network for proper functioning. In addition, it is 
currently unknown what effect ALP/ELP dysregulation associated with AD has on MSE 
activity. Suggestively, the mechanism underlying the regulation of MSE turn-over also remains 
largely unknown. A potential interaction between ALP/ELP dysregulation and MSEs may 
provide a novel association between Tau dissociation and subsequent microtubule collapse 
as observed in AD. 





Much about the AD aetiology still remains largely unknown, indicating the dire need for further 
investigation. Elucidating key intracellular pathways of neurons, such as the ALP, in 
homeostasis and in the AD pathogenesis may help in the development of effective therapies 
targeted at slowing down progression and ultimately curing the disease instead of treating the 
symptoms. 
 
1.2 Protein degradation  
1.2.1 Autophagy-Lysosomal Pathway  
Autophagy is a major lysosomal-mediated catabolic process which is responsible for the 
degradation of long -lived proteins and damaged organelles. It serves as a stress-mediated 
response, i.e. during nutrient deprivation, but is also active under basal conditions to maintain 
functional turn-over of proteins and organelles, thus preventing their abnormal accumulation 
(Loos et al. 2013; Mizushima et al. 2008; Klionsky 2005). There are mainly three known types 
of autophagy; namely chaperone-mediated autophagy, microautophagy and macroautophagy 
(Fig 1.1). All share a common end in which the isolated protein is digested by lysosomal 
enzymes resulting in the release of nutrients, mainly amino acids, back into the cytosol 
(Mizushima et al. 2008; Klionsky 2005).  
The lysosome is a single membrane organelle that contains a vast amount of soluble and 
membrane associated hydrolases with characteristic acidic pH optima, capable of digesting 
macromolecules and cell constituents (Nixon 2007). These hydrolases include nearly 24 
different types of a protease called cathepsins, which act across a broad range of low pH’s 
with varying catalytic classes and peptide specificities (Nixon 2007). The lysosomal lumen low 
pH environment is maintained by a vacuolar- ATPase (v-ATPase) membrane protein that 
pumps protons into the vesicle (Deter et al. 1967). Lysosomal dysfunction has been 
associated with the AD pathogenesis (Nixon et al. 2008). 
In chaperone-mediated autophagy, the protein destined for degradation is recognised by a 
chaperone complex. HSC70, a protein in the chaperone complex recognises the proteins 
through a KFERQ motif located on the target protein peptide sequence. The substrate-
chaperone complex is then transported to the lysosome where it binds to the lysosome 
associated membrane protein type 2A (LAMP-2A) receptor (Cuervo 2010). This binding allows 
for the translocation of the protein across the lysosomal membrane into the lumen, where it is 
degraded. In microautophagy, part of the lysosomal membrane invaginates and pinches off 
small vesicles containing trace amounts of cytosol and proteins, into the lysosomal lumen. 





Macroautophagy, the overall contributing form to the autophagic rate of protein degradation in 
most cells, occurs through sequestration of large amounts of cytosolic proteins and organelles 
by a double membrane vesicle to form a structure termed an autophagosome. The 
autophagosome fuses with the lysosome releasing its contents into the lumen and allowing 
protein digestion to take place (Singh & Cuervo 2011). 
Macroautophagy (hereafter referred to simply as autophagy) is essential for cell viability. 
Functional disruption of autophagy leads to the accumulation of undigested proteins, which 
may interact with normal molecular functions and elicit pathological responses, therefore 
regulation of autophagy is a tightly controlled and complex process (Hara et al. 2006; Nixon & 
Yang 2011). 
 
1.2.1.1 Autophagy regulation 
Autophagy occurs at basal levels under normal homeostatic conditions, with rates higher in 
neural tissue (Mizushima 2003). The rate of protein degradation through autophagy is referred 
to as autophagic flux (Mizushima & Yoshimori 2007). Basal activation helps in the 
maintenance of protein quality and turn-over. The process of autophagy can be categorized 
into several stages, namely; induction, cargo recognition and selection, vesicle formation, 
autophagosome-lysosome fusion, cargo digestion, release of substrates into the cytosol and 
finally feedback ( Loos et al. 2013; Loos et al. 2014). More than 30 genes and their variant 
transcripts (termed autophagy-related proteins or Atg) have been found to participate in 
Figure 1.1: The three autophagy pathways. Macroautophagy, Microautophagy and Chaperone-Mediated 
Autophagy (CMA). HSP70 – Heat Shock Protein 70; LAMP-2A – Lysosome Associated Membrane Protein type 
2A. 





autophagy induction and regulation. There are several signalling mechanisms that regulate 
autophagy, but the most characterised is the mTOR pathway, which is activated in response 
to nutritional changes or periods of stress (Singh & Cuervo 2011). 
The mTORC1 (mammalian target of rapamycin complex 1) protein complex and AMPK 
(Adenosine Monophosphate Kinase) are central to the induction of autophagy, serving as a 
nutrient sensor and a master regulator respectively (Loos et al. 2013). In a fed state mTORC1 
phosphorylates and actively recruits ULK1 into a complex with Atg13 and FIP200, keeping 
them inactive. In a state of nutrient deprivation or stress, AMPK is activated and 
phosphorylates mTORC1 – relieving its inhibitory effect on ULK1. The activated ULK1-Atg13 
complex shuttles Atg9 to the site of autophagosome formation. ULK1 phosphorylates AMBRA, 
a component of the PI3K CIII complex which triggers its recruitment to the growing isolation 
membrane, i.e. the phagophore (Fig 1.2) (Singh & Cuervo 2011). In addition to AMBRA, the 
complex consists of Beclin-1, Atg14, Vps34 and Vps15. The PI3K complex generates PI3P, 
which binds to its effector WD repeat domain phosphoinositide-interacting (WIPI) type 1 and 
2 proteins. The binding in turn catalyses two ubiquitination-like reactions, which requires the 
actions of Atg9, to expand the autophagosomal membrane. In the first such reaction Atg5 
forms a complex with Atg12 facilitated by Atg7 and Atg10 (Nixon, 2013) (Fig 1.2). Another 
complex consisting of Atg5-Atg12-Atg16 attaches to the forming membrane and, through the 
action of the first complex, facilitates the lipidating reaction between 
phosphatidylethanolamine and LC3-I. This lipidation process forms LC3-II which facilitates the 
closure of the membrane, forming an autophagosome (Ichimura et al. 2000) (Fig 1.2). Atg4 
then removes LC3-II bound to the outside of the membrane and LC3-II bound to the inside of 
the membrane is degraded once the autophagosome binds to the lysosome to form an 
autophagolysosome or simply termed an autolysosome. LC3-II protein levels thus directly 
correlate with the number of autophagosomes in the cell (Mizushima & Yoshimori 2007) 
The process reaches an end point when the cargo is degraded and amino acids and other 
nutrients are released back into the cytosol via permeases located on the autolysosomal 
membrane (Loos et al. 2013). Lysosomes are then reformed containing mainly hydrolases. 
Interestingly, it has been found that this reformation process is also regulated by mTOR (Yu 
et al. 2010). 
The source of the autophagosomal membrane during autophagosome biogenesis has been 
the subject of contentious debate in the autophagy field. In recent years many studies have 
suggested that multiple organelles are the source of the membrane, including the endoplasmic 
reticulum (ER), plasma membrane and even recycling endosomes (Shibutani & Yoshimori 
2014). However, the general consensus in mammals is that it is likely the ER which is the main 





source, although the exact molecular mechanisms underlying its role in autophagosome 
membrane biogenesis are yet to be elucidated (Shibutani & Yoshimori 2014) 
Furthermore, autophagy may also occur in a selective or non-selective manner. In selective 
autophagy, p62 (also known as sequestersome 1/SQSTM1) acts as an adapter protein 
between LC3-II residues on the forming phagophore and targeted poly-ubiquinated proteins 
(Klionsky 2005; Singh & Cuervo 2011). Since p62 and LC3-II are both degraded during 
autophagy, their lysosomal-dependent turnover has emerged as a measure of relative 
autophagic flux which can reliably be determined through Western blot analysis. Although p62 
is an indicator of selective autophagy, deducing results based on protein selectivity becomes 
complicated since it is also an autophagy target (Bjorky et al. 2005; Mizushima & Yoshimori 
2007; Rubinsztein et al. 2009). 
 
 
1.2.2 Endosome- Lysosome Pathway 
Closely linked to autophagy is the endocytic pathway, in which cargo-receptor molecules from 
the cell surface are internalised after which they are either recycled, modulated or ultimately 
digested (Fig. 1.3) (Hu et al. 2015). It is composed of a series of vesicular structures that differ 
according to their localisation and function within the pathway. They are broadly organised 
into three categories namely early endosomes (EEs), recycling endosomes (REs) and late 
Figure 1.2: The regulation of macroautophagy (autophagy).  Induction, elongation of the autophagosomal 
membrane (phagophore) and vacuole formation. Atg – Autophagy Related Protein; ULK - unc-51 like autophagy 
activating kinase 1; FIP - focal adhesion kinase family interacting protein; mTORC1 - mammalian Target Of 
Rapamycin Complex 1; AMBRA - Activating Molecule in Beclin 1-Regulated Autophagy; VPS - vacuolar protein 
sorting; PI3P - Phosphatidyl-Inositol-3-Phosphate; WIPI - WD-repeat protein interacting with phosphoinositides. 
Adapted from Nixon 2013 





endosomes/multi-vesicular bodies (LEs) (Huotari & Helenius 2011). The pathway is initiated 
by the internalisation of cargo and the formation of EEs, which have two potential trafficking 
destinies, either ending in the recycling or the digestive pathway.  
1.2.2.1 Recycling Pathway 
EEs usually form from clathrin coated pits on the plasma membrane, budding off internally to 
form vesicles. These vesicles can then fuse with one another or ultimately with pre-existing 
EEs, a process that is facilitated by the GTPase, Rab5 (Hu et al. 2015). EEs form with a low 
intraluminal pH to facilitate receptor ligand dissociation, thereby acting as a sorting station by 
allowing the newly freed receptors to be trafficked back to the plasma membrane or the Trans-
Golgi-Network (TGN) via REs and Retromer complexes respectively (Hu et al. 2015; Hunt & 
Stephens 2011; Huotari & Helenius 2011). The Retromer is a protein complex that exists for 
exclusive retrograde transport of cargo between the TGN and endosomes. It is composed of 
sorting nexins (SNXs) and cargo recognition trimers, such as Vps26–Vps29–Vps35, that 
recognise proteins on the cytosolic membrane of endosomes (Huotari & Helenius 2011). 
When trafficked from EEs to REs, the process is accompanied by an association of Rab5 to 
that of Rab4 and Rab11. Of note, the majority of cargo internalised by the endosomes in 
mammalian systems is recycled back to the plasma membrane (Steinman et al. 1983). 
1.2.2.2 Digestion Pathway 
EEs destined for digestion are trafficked, while maturing into late endosomes, from the 
periphery to the cell centre. A number intraluminal vesicles (ILVs) develop, an important 
maturation step for the transition into late endosomes/multi-vesicular bodies. The lumen also 
becomes increasingly acidic with the help of v-ATPase pumps located at the endosomal 
surface. Maturation is accompanied by a change of association with Rab5 to Rab7, a process 
termed “Rab conversion”. LE  trafficking usually ends with lysosomal fusion and the digestion 
of their cargoes, but may also lead to fusion with autophagosomes prior to lysosomes, to form 
hybrid structures termed amphisomes (Nixon 2007). Additionally, LEs may also exchange 
ILVs with each other or with lysosomes through a “kiss and run” action before full lysosomal 
fusion takes place (Huotari & Helenius 2011; Nixon 2007). 
Digestion of late endosomes is tightly controlled by the ESCRT (endosomal sorting complex 
required for transport) systems, which sort ubiquitin tagged proteins for degradation. The 
ESCRT machinery has four distinct complexes; namely ESCRT-0, -I, -II and –III. It acts  in a 
“conveyor belt model” by sequentially sorting ubiquinated proteins into LEs starting with 
ESCRT -0 and ending with –III, each having a distinct function in the system (Hu et al. 2015). 
 








The third main proteolytic process is the UPS (Fig. 1.4). This highly regulated process initiates 
a specific form of proteolysis by targeting small proteins. Only proteins conjugated to a poly-
peptide ubiquitin molecule (Ub), through a series of reactions, are degraded. 
The conjugation of the substrate to Ub is regulated through three types of enzymes; namely 
E1, E2 and E3 ligases. Ub is first activated by E1 type enzymes, through the hydrolysis of 
ATP. During activation a high energy thiol-ester Ub-AMP intermediate is formed. The E1 
enzymes are the least physiologically regulated, but play an important role in maintaining the 
threshold of UPS initiation. The two most commonly known enzymes to initiate ubiquitination 
are UBA1 and UBA6 (Schulman & Wade Harper 2009). Activated Ub is transferred to an E2 
type enzyme which then facilitates the conjugation of Ub to the substrate through E3 ubiquitin 
ligases. The human genome encodes for 40 isoforms of E2 type enzymes, indicating some 
degree of substrate specificity. E3 type enzymes ligate the Ub-molecule to a Ɛ-amino group 
of a lysine residue on the substrate. A poly-Ub chain grows by conjugation of a new Ub 
molecule onto one of seven different lysine residues on the first Ub. E3 type enzymes are 
Figure 1.3: The endosomal pathway: The process of endocytosis (A) Autophagosome; (AL) 
Autophagolysosome; (Amph) Amphisome; (EE) Early Endosome; (EL) Endolysosome; (LE) Late 
Endosome; (L) Lysosome; (RE) Recycling Endosome. Adapted from Hu et al. 2015  





highly diverse with an estimated 600 isoforms - a number which may indicate their determining 
presence in UPS-mediated substrate selectivity (Lee et al. 2013).  
 
 
The poly-ubiquinated substrate is degraded through an ATP-dependent reaction by a 
proteolytic complex known as the 26S proteasome. The 26S proteasome is a ~2.5 MDa 
holoenzyme structure composed of multiple subunits. Ubiquitin is not degraded, but the Ub-
chain is disassembled by de-ubiquitinating enzymes (DUBs) and subsequently recycled into 
the cytosol. In addition, DUBs can disassemble Ub-chains on erroneously tagged substrates 
to prevent their degradation (Hegde & Upadhya 2011; Lee et al. 2013). 
The 26S holoenzyme (Fig 1.5) is composed of a 20S cylindrical catalytic core and two 19S 
regulatory subunits attached to either end of the core. The 20S subunit consists of two outer 
rings with seven α subunits (α1-α7) in each ring and two inner rings consisting of seven β 
subunits (β1-β7) (Fig. 1.5). The catalytic activity is provided by three of the seven β subunits 
(β1, β2 and β5) with active sites at their N-termini, which are located on the inside of the core 
particle catalytic chamber (Hegde & Upadhya 2011) (Fig. 1.5). The opening of the chamber 
has a pore size of ~13Å in diameter. Unfolding occurs through the action of ATPases located 
Figure 1.4: The UPS. E1 enzymes conjugate with Ub molecules, allowing for their activation. The E1 
enzyme then transfers the activated Ub molecule to the E2 enzyme which translocates the activated 
Ub molecule to the substrates that require proteasomal degradation. Finally the E3 enzyme targets the 
polyubiquitinated substrate to the 26s proteasome for substrate degradation. DUBs recycle Ub 
molecules as well as de-ubiquitinate erroneously tagged substrates. Adapted from Hegde 2010 





at the base of the 19S regulatory subunit. The 19S is composed of 6 ATPase subunits; Rpt1-
Rpt6 and four non-ATPase subunits; Rpn1, Rpn2, Rpn10 and Rpn13. Rpn10 and Rpn13 act 
as receptors that recognise the ubiquinated substrate. The 19S also has a “lid” consisting of 
non-ATPase subunits; Rpn3, Rpn5, Rpn6-9, Rpn11-12 and Rpn15). Rpn11 and Rpn12 
provide structural integrity to the complex (Lee et al. 2013; Weissman et al. 2011) (Fig. 1.5). 




1.2.4 Proteostatic Perturbations in AD 
In addition to the Aβ plaques and NFT aggregates observed in AD brain tissue are gross focal 
swellings of neuronal axons and dendrites, which are termed dystrophic neurites. When 
viewed with an electron microscope these neurites appear to be severely impacted, displaying 
electron dense lysosomal bodies containing undigested protein (Fig. 1.6). This has been 
attributed to dysfunction of both the ALP and ELP (Nixon & Yang 2011; Nixon et al. 2005; 
Cataldo et al. 2000). ALP and ELP dysfunction have in fact been linked to Aβ pathology, as 
endosomes and autophagosome are known sites of Amyloid Precursor Protein (APP) 
production and modulation (Perez et al. 2015; Cataldo et al. 2000). The ALP and UPS are 
both important in the turn-over of Tau and dysfunction of these systems have been shown to 
promote Tau aggregation (Hamano et al. 2008; Hamano et al. 2009; Wang & Mandelkow 
2012; Lee et al. 2013) Of note, lysosome-related dysfunction occurs very early in the disease, 
Figure 1.5: The 26S proteasome. The 26S proteasome consists of a 20S core subunit and two 19S 
regulatory subunit on either end. Adapted from Weissman et al. 2011 





preceding both Aβ and Tau pathology, which may suggest a major role for lysosomal 
dysfunction in the manifestation of AD (Perez et al. 2015; Cataldo et al. 2000). In fact, Aβ has 
been found to localise in autophagosome membranes and the pathological induction of 
autophagosome synthesis as well as defective autophagosome clearance have both been 
suggested as primary sources of Aβ in AD (Nixon 2007). 
Additionally, UPS dysfunction has also been linked to Tau pathology in late AD. The available 
evidence suggests that NFT aggregation may in fact be the cause of this dysfunction rather 
than a consequence. It is theorised that aggregated and hyperphosphorylated Tau blocks the 
pores of the proteasome, thus rendering it dysfunctional (Lee et al. 2013). 
Moreover, the build-up of these vesicles containing undigested protein impacts normal axonal 
transport of other vesicles and organelles, such as autophagosomes and mitochondria, along 
the microtubule network (Lee et al. 2011; Torres et al. 2012). However, the exact molecular 
mechanisms leading to the onset of these axonal transport deficits remain elusive. 
 
 
Figure 1.6: Ultrastructural appearance of autophagic vacuoles in AD brain. (a) “Ultrastructural 
appearance of autophagic vacuoles in AD brain”. (b, c) “Highly purified subcellular fractions from mouse 
liver. Dystrophic neurites contain abundant vesicles with a range of distinct morphologies similar to 
those of AVs highly purified from mouse liver by a well-established subcellular fractionation techniques”. 
Source: Nixon et al. 2005. 
  





1.3 Microtubulin Network 
1.3.1 Microtubulin Dynamics 
 The microtubule system is an essential constituent of the cytoskeleton, which plays a major 
role in vesicular transport, neuronal morphogenesis, cell migration, intracellular organisation 
and differentiation (Avila 1992). It is a hollow tubular structure, with a diameter of 
approximately 24 nm, composed of α- and β-tubulin heterodimers (Avila 1992). The two ends 
are structurally differentiated into positive and negative poles, with β-tubulin orientated 
towards the former and α-tubulin towards the latter (Fig.1.7). Polymerisation is faster on the 
positive end which allows extension into the cytoplasm whilst the negative end is anchored to 
a nucleated area known as the MTOC (microtubule organising centre) located near the 
centrosome of the cell (De Forges et al. 2012). Anchoring and capping of the negative pole 
requires another tubulin isomer known as γ-tubulin, which forms the γ –TuRC (γ -tubulin ring 
complex). As such, polymerisation from the negative end is rarely, if at all observed in vitro 
(van der Vaart et al. 2009). Polymerisation of the microtubule occurs in a very dynamic fashion, 
a process termed dynamic instability (Mitchison & Kirschner 1984). This behaviour entails 
phases of growth and shrinkage of the polymer separated by periods of catastrophe, i.e. the 
transition from growth to shrinkage, and rescue, i.e. the transition from shrinkage to growth. 
To facilitate polymerisation, GTP bound to β-tubulin, is hydrolysed. The short period between 
GTP hydrolysis and polymerisation allows for the formation of a GTP-tubulin cap which 
stabilises the process. A loss of the GTP-tubulin cap results in rapid depolymerisation, i.e. 
catastrophe. 
The microtubule determines the polarity of neuronal cells in higher eukaryotes. In the axon, all 
microtubules have a positive-end orientation, whereas the dendrites have mixed orientations 
(De Forges et al. 2012). Specialised motor proteins known as Kinesins and Dyneins facilitate 
the transport of cellular machinery along the microtubule. In addition, polarised arrays of 
microtubules are generated through transport of microtubule polymers from the MTOC in a 
Dynein-dependent manner (Ahmad & Baas 1995). 






1.3.1.1 Microtubule Regulation 
During cell growth and branch formation, microtubules are severed at specific sites to generate 
shorter repeats through the actions of specialised microtubule severing enzymes (MSEs). 
Such repeats are subsequently transported via motor proteins to the site of branch formation 
and are polymerised throughout the newly grown neurite. Severing generally occurs through 
the action of mainly two enzymes; namely Katanin and Spastin (discussed further in 1.3.2). 
Generation and transport of these short microtubule repeats is critical to the growth of the 
microtubule network and the viability of the cell (Yu et al. 2008). 
Microtubules are also prone to post-translational modification such as tyrosination, 
glutamylation and acetylation. Tyrosination of the microtubule is the result of the enzyme 
tubulin-tyrosine ligase, which acts by catalysing the addition of a tyrosine residue to the C-
terminal of the tubulin tail (De Forges et al. 2012). Tyrosination of tubulin has been shown to 
induce a positive effect on stabilisation, by recruiting stabilising factors and affecting 
destabilising MAP binding affinity (Wloga & Gaertig 2010). Polyglutamylation of the 
microtubule has been found to increase binding affinity of not only several neuronal MAPs and 
motor proteins, but also the recruitment of Spastin (Bonnet et al. 2001; Lacroix et al. 2010). 
Acetylation occurs on the α-subunit of the microtubule heterodimer and is associated with 
increased binding for motor proteins to the microtubule (De Forges et al. 2012). Acetylated 
tubulin has also long been associated with stability, but recent evidence suggests that the 
acetylation may have a modest or no effect at all on stability (Howes et al. 2014; Quinones et 
al. 2011). In fact, it was shown that the microtubule binding of Histone deacetylase 6 (HDAC6), 
a deacetlyating enzyme, showed stabilizing effects rather than acetylation itself (Asthana et 
Figure 1.7: The structure of the microtubule. The microtubule consists of αβ-heterodimer 
microtubulin. Indicated are the directions of transport along the network. 





al. 2013). It has also been shown that the fusion between autophagosomes and lysosomes is 
dependent on the association with acetylated microtubulin, which usually occurs close to the 
centrosome of the cell (Schulze 1987; Xie et al. 2010). Although the role of acetylation in 
tubulin stability has been a topic of debate, the consensus agrees that acetylated tubulin is a 
suitable marker for stable microtubulin. 
Microtubules are further extrinsically regulated through MAPs, which help facilitate 
polymerisation of the microtubule by stabilising and destabilising the process. The most 
abundantly studied stabilising MAPs are the neuron-specific Tau (discussed later in 1.3.1), 
MAP2 and the non-neuronal MAP4 (De Forges et al. 2012). 
Lastly, other known important classes of stabilising MAPs are plus end tracking proteins 
(+TIPs), that dynamically track the polymerisation of the positive end of the microtubule, and 
destabilising MAPs, such as stathmin and SCG10 that are important for neuronal growth 
(Akhmanova & Steinmetz 2010; Grenningloh et al. 2004). These proteins will, however, not 
be discussed for the purposes of this review as it is beyond the scope of the research project. 
 
1.3.2 MAPs  
1.3.2.1 Tau 
Tau is a hydrophilic structural MAP that is predominantly localises in the axons of neurons. 
Tau supports the dynamic polymerisation of the microtubule as well as allowing post-
translational modification of the microtubule network. There are six isoforms of Tau, which are 
all derived from the Tau gene (MAPT) located on chromosome 17q21, through alternative 
mRNA splicing (Fig 1.8). These isoforms differ from each other in length, domain composition 
and post-translational modifications. Only 4 isoforms are expressed in the adult brain (Avila et 
al. 2004). 
The Tau protein structure is characterised by a projection domain containing the amino-
terminal and the microtubule binding domain containing the carboxyl-terminal. The projection 
domain contains a region composed of acidic residues with one, two or no insertions (N) of 
~29 amino acid long repeats (depending on the isoform) and a proline-rich region (Lee et al. 
2013). The microtubule binding domain comprises of three or four semi-conserved “pseudo-
repeats”(R) of ~31 amino acids in length. Different isoforms contain either repeats R1-R4 or 
R3-R4. In addition, the projection domain protrudes away from the microtubule surface, 
possibly as the result of an electrostatic repulsion (Ballatore et al. 2007). 
Tau is also subject to post-translational modifications including glycosylation, ubiquitination, 
acetylation and phosphorylation, which occurs on the serine/threonine residues. There are 





~79 serine/threonine phosphorylation sites on the longest isoform of Tau which has a 441 
amino acid sequence. Phosphorylation of Tau occurs through the action of various enzymes 
including cdk5, GSK3-β, p38 and JNK (Flaherty et al. 2000). Phosphorylation regulates the 
binding affinity of the Tau protein to the microtubule – the more phosphorylated, the less 
binding affinity it has for microtubulin. Phosphorylation is also developmentally regulated - 
foetal neurons have a high degree with the overall rates decreasing with age (Stoothoff & 




1.3.3 Tau Pathology and Neurofibrillary Tangles 
In AD, dissociated and abnormally hyperphosphorylated Tau termed “pretangle material”, 
initially accumulates in a non-fibrillar form (Braak & Del Tredici 2015). Pretangles arrange in a 
β-sheet conformation to form paired helical filaments (PHF) or straight filaments (SF). NFTs 
almost exclusively consists of PHFs, but also contain other proteins such as unphosphorylated 
Tau, MAP1, MAP2, as well as ubiquitin molecules (Lee et al. 2013; Alonso et al. 1994). 
The intracellular levels of hyperphosphorylated Tau increase before NFT formation in AD 
affected brains (Bancher et al. 1989). It is not entirely known what initiates this 
hyperphosphorylation of Tau, but dysregulated activity of specific protein kinases and 
phosphatases have been found to facilitate this modification. The identified kinases include 
GSK3β, cdk5, MARK, Fyn, and phosphatases PP2A and PP2B (Plattner et al. 2006; Kimura 
Figure 1.8: The 6 isoforms of the Tau protein. The different Tau isoforms vary in length and amino 
acid composition. N – N-terminal; N1/N2 – Acidic residue insertion; PD – Proline rich region; R – 
Pseudorepeat insertion; C – C-terminal. 





et al. 2014; Mandelkow et al. 2004; Wang et al. 2007). Whether an increase in activity of 
phosphorylating kinases or a decrease in dephosphorylating enzymes contributing to Tau 
hyperphosphorylation is not known, as evidence for both of these scenarios has been 
identified in AD brain tissue (Wang et al. 1995; Wang et al. 1996; Wang et al. 2007). 
In FAD, Aβ aggregation is a characteristic initial event that leads to hyperphosphorylation of 
Tau downstream and it appears that the toxic effects of Aβ pathology are dependent on the 
missorting and hyperphosphorylation of Tau (Armstrong 2014; Zempel et al. 2013). Tau 
aggregates also correlate better with the clinical progression of AD as opposed to Aβ (Braak 
& Braak 1991). 
Tau pathology can also occur in the absence of Aβ aggregation in diseases termed 
Tauopathies. Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-
17) is one such Tauopathy that is thought to result from a mutation in the MAPT gene, which 
produces mutated Tau (P301L) that is prone to spontaneous aggregation and NFT formation 
(Boxer et al. 2013). 
It is thought that NFTs elicit their toxic effect by impairing axonal transport, because of the role 
Tau plays in microtubulin dynamics and the cytoskeleton changes observed in early AD. 
Particularly the “disintegration’ of microtubulin networks – is a mechanism that is still poorly 
understood (Braak et al. 1994; Baas & Qiang 2005). It has been suggested that there is an 
increase in Tau protein levels and subsequent binding on the microtubule. This causes 
anterograde transport to be blocked by limiting binding of motor proteins (Baas & Qiang 2005). 
The cell then hyperphosphorylates Tau to combat this effect and allows motor protein binding, 
but in doing so also exposes the network to destabilising proteins such as MSEs and stathmin 
(Baas & Qiang 2005; Mandelkow et al. 2004). Furthermore, Tau appears to induce alterations 
in NMDA receptor phosphorylation by interfering with the action of the kinase Fyn (Ittner & 
Götz 2011). 
What causes the initial accumulation of Tau remains to be determined, however since Tau is 
a substrate of both the ALP and UPS pathways, proteostatic perturbations are likely to play a 
key role in this process (Lee et al. 2013; Wang & Mandelkow 2012; Liu et al. 2009; Hamano 
et al. 2008). 
 
1.3.4 Microtubule severing enzymes 
Microtubule severing enzymes (MSEs) are specialised proteins capable of cleaving the 
microtubule (Yu et al. 2008). They function to generate shorter microtubule repeats, which are 
required and transported via motor proteins to sites of branch formation, but are also critical 





to the maintenance of cellular homeostasis (Yu et al. 2005; Yu et al. 2008). Spastin and 
Katanin are the most studied MSEs in neurons and have received much attention in recent 
years, especially in their potential involvement in microtubulin instability associated with AD 
pathogenesis (Jean & Baas 2013).  
 
 1.3.4.1 Katanin 
Katanin is a heterodimeric protein comprising of two subunits, P60 and P80, which are thought 
to form a hexameric ring around the microtubule. The P60 subunit cleaves the microtubule 
lattice by hydrolysing ATP, whilst P80 targets it to the centrosome for other processes (Yang 
et al. 2013). It was recently shown that Katanin p60 in fact severs the lattice by generating a 
mechanical force between the hexameric pore and the acidic tail residues of both α and β 
tubulin dimers (Fig 1.9) (Johjima et al. 2015). Severing of the lattice creates short microtubules 
within cellular compartments, such as in the axon or dendrites for branch formation. It was 
expected that both subunits were equimolar in cytosolic concentration, but current research 
indicates that concentrations of both proteins vary significantly relative to each other, be it the 
developmental state of the organism, tissue type and/or cellular localisation. Additionally, it 
has been found that P60 can sever microtubules in the absence of P80, but may operate more 
efficiently in its presence (Yu et al. 2005). Protein levels are higher during development, but 
diminish over time. Neurons are known to have a higher concentration of Katanin relative to 
other tissue types. In addition, cytosolic protein levels are higher during axon formation and 
diminish once their targets are reached, indicating a significant role in axon generation (Yang 
et al. 2013; Karabay et al. 2004). 
The relative protein levels of Katanin within neurons at any time should theoretically sever all 
the microtubules within the cell – which questions how its activity is regulated. Protein levels 
are higher in mitotic cells compared to interphase cells, suggesting a link between Katanin 
regulation and phosphorylation (McNally et al. 2002). However, Katanin has so far not been 
found to be a target of phosphorylation. Thus, it is likely that phosphorylation of other proteins 
regulates binding activity of Katanin, particularly those interacting with the microtubule. In 
extracts of xenopus eggs arrested in interphase, it was revealed that XMAP4, the human 
analogue of MAP4, acts as an inhibitor of Katanin severing activity (Vale 1991). Of note, MAP4 
is a major non-neuronal MAP and shares very similar microtubule-binding domain structure 
with neuronal MAP2 and Tau (Dehmelt & Halpain 2005). Importantly, in neurons Tau protects 
the microtubule from severing by Katanin, by only allowing severing at sites of branch 
formation where Tau has dissociated (Chen et al. 2008; Qiang et al. 2006). Another study 





revealed that Katanin severing is enhanced when α-tubulin is acetylated and decreased upon 
deacetylation, suggesting another potential regulatory mechanism (Sudo & Baas 2010). 
It remains unknown how the turnover of Katanin is regulated. A study conducted in cultured 
hippocampal neurons described a molecular relationship between Katanin, HSP70 and 
USP47, a ubiquinating enzyme. It is suggested that USP47 plays a role in the control of axonal 
growth by counteracting CHIP (C terminus of Hsp70-interacting protein)-mediated 
ubiquitination and destabilisation of Katanin p60. A potential complex-interaction between 
Katanin p60 and USP47 is yet to be elucidated (Yang et al. 2013). 
Currently there are no known genetic mutations or specific diseases that have been linked to 
Katanin expression or activity. 
 
1.3.4.2 Spastin 
Spastin in its active state, similarly to Katanin, is thought to form a homohexameric ring around 
the microtubule dimer acidic tails and to induce mechanical severing through ATP hydrolysis 
(Fig 1.10) (Eckert, Link, et al. 2012; Eckert, Le, et al. 2012). The protein is encoded by the 
SPG4 gene (Claudiani et al. 2005). Mutations of SPG4 are the cause of 40% of cases of 
Autosomal Dominant Hereditary Spastic Paraplegia (AD-HSP). HSP is a genetically 
heterogeneous disease characterised by retrograde axonal degeneration of corticospinal 
tracts as well as posterior columns, which leads to weakness and spasticity of the lower limbs 
(Charvin et al. 2003; Papadopoulos et al. 2015). Spastin is ubiquitously expressed, but most 
abundantly in neural tissue, with the exception of glial cells (Dráberová et al. 2011). Two 
Figure 1.9: Katanin p60 mechanism of action. Katanin p60 severs the lattice by generating 
a mechanical force between the hexameric pore and the acidic tail residues of both α and β 
tubulin dimers. Adapted from Johjima et al. 2015 





isoforms, M87 and M1, exist through the translation of alternative start codons of the SPG4 
gene. M1 is the full length 616-amino form and M87 is the truncated form, lacking the N-
terminal 86 amino acid residues (Claudiani et al. 2005). M87 is cytosolically localised, and is 
usually more abundant than M1, which favours ER and nuclear localisation (Claudiani et al. 
2005). However, M1 appears to be the predominant isoform in neurons, particularly in the 
adult spinal cord (Solowska et al. 2008). 
Like the other proteins in this family, Spastin has diverse cellular functions, but recently lipid 
metabolism and activity in membrane modelling has also been reported, specifically in 
endosome formation, sorting and trafficking (Lumb et al. 2012; Connell et al. 2009; 
Papadopoulos et al. 2015). Spastin interacts with ESCRT-III, which controls the formation and 
sorting of cargo into internal vesicles within late endosomes/multi vesicular bodies. It was 
suggested that Spastin cleavage of tubules of early endosome compartments is required for 
functional cargo sorting and trafficking. This was indeed suggested when cells knocked down 
for Spastin showed an increase in early endosomal tubulation and decreased sorting (Allison 
et al. 2013). This may explain the swollen axons and defective retrograde and anterograde 
vesicle transport, which results in cargo accumulation seen in models and patient derived 
tissues with SPG4 mutations (Tarrade et al. 2006; Kasher et al. 2009). Of note, this shows an 
insidious similarity with the gross accumulation of vesicles containing undigested protein 
observed in AD affected neurons (Nixon & Yang 2011). 
Spastin has been shown to preferentially bind to and sever poly-glutamylated tubulin. Amyloid-
β induced Tau missorting has directly been shown to increase tubulin poly-glutamylation in 
dendrites by recruiting TTLL6 (tubulin tyrosine like ligase 6), the enzyme that confers the 
polyglutamylation modification (Lacroix et al. 2010). The mechanism underlying Tau 
missorting and subsequent increase in TTLL6 recruitment remains to be elucidated (Zempel 
& Mandelkow 2014). Spastin, unlike Katanin, can sever the microtubule independent of the 
presence of Tau presence on the lattice (Sudo & Baas 2010). 
Although partial knowledge exists on Spastin activity and regulation, much remains unknown, 
particularly how protein turn-over is controlled and if autophagy plays a role in this regard. 







1.3.5 Molecular motor proteins 
Transport of cytoplasmic cargo along microtubules is critical to the functioning of cells, 
especially in neurons. Defects in transport have clearly been identified in multiple 
neurodegenerative pathologies (Dixit et al. 2008; Kasher et al. 2009; Lee et al. 2011). 
Intracellular transport is mainly carried out by two types of molecular motors; namely Dynein, 
usually a retrograde motor protein operating from positive to negative ends of the microtubule, 
and Kinesin, an anterograde motor protein operating from negative to positive ends of the 
microtubule. They are also part of the AAA enzyme family and hydrolyse ATP to generate 
force for movement. Both have numerous isoforms with their own cargo specificities and 
adaptor proteins (Goldstein & Yang 2000). 
Dynein is the larger of the two proteins and functions as the main retrograde motor. In order 
to function fully, Dynein requires a large multiprotein complex called dynactin that facilitates 
its processivity and possibly regulates its activity (Goldstein & Yang 2000; Dixit et al. 2008). 
Although mainly a retrograde motor, Dynein is also involved in the bidirectional transport of 
newly generated shorter microtubules, particularly to sites of new growth (i.e growth cones) 
(Myers et al. 2006; Ahmad et al. 2006). 
Dynein is critical in the transport and fusion of autophagosomes and lysosomes along the 
microtubulin network (Jahreiss et al. 2008). Altered Dynein function leads to the accumulation 
of autophagosomes, highlighting the ALP reliance on Dynein based transport (Yamamoto et 
al. 2010). Furthermore, it seems that MAPs (specifically Tau) impose a spatio-temporal 
regulation on Dynein and Kinesin movement. Tau binding on the microtubule acts as a spatial 
Figure 1.10: Spastin mechanism of action. Spastin forms a homohexameric ring around the 
microtubule dimer acidic tails and induces mechanical severing through ATP hydrolysis. Adapted from 
Eckert, Link, et al. 2012. 





obstacle for the motor proteins and prevents movement of cargo (Mandelkow et al. 2004; Baas 
& Qiang 2005). When encountering this “roadblock”, Dynein appears to move in the opposite 
direction while Kinesin will detach from the microtubule. Kinesin also appears to be more 
affected by these obstacles than Dynein (Dixit et al. 2008; Baas & Qiang 2005). 
Furthermore, both Kinesin and Dynein have been found to transport vesicles that contain 
amyloid precursor protein (APP). Subsequent studies have shown that this process is 
dependent on the actions of presenelin, a transmembrane protein involved in amyloid 
metabolism (Gunawardena et al. 2013). 
 
1.4 Amyloid Metabolism 
Although not a key focus in this study, the role of amyloid-β requires particular focus as it is 
thought to play critical role in the AD pathogenesis. In 1992, the scientists Hardy and Higgins 
were so convinced that Aβ was the cause of AD that they postulated the amyloid cascade 
hypothesis, which details disease progression with amyloid beta deposition as the initiator of 
the pathology (Hardy & Higgins 1992). Amyloid Precursor Protein (APP), as the name 
suggests, is the precursor to Amyloid-β (Aβ), the protein that mainly composes the senile 
plaques observed in AD. The APP gene is located on chromosome 21 (Musiek & Holtzman 
2015). 
Although the physiological function of APP is not entirely clear, it has been shown to have 
putative roles in signal transduction, cell migration and adhesion, as well as membrane 
trafficking (Nixon 2007; Mokhtar et al. 2013). APP is generated in the Trans-Golgi-Network 
(TGN), after which it is transported to the plasma membrane via the ELP. Here it is processed 
in either of two pathways; the so-called amyloidogenic and non-amyloidogenic pathway (Fig. 
1.11) (Rajendran & Annaert 2012). 
In the amyloidogenic pathway, Aβ is generated by the sequential cleavage of APP by the 
proteases β-secretase and γ-secretase (Nixon 2007; Rajendran & Annaert 2012). The 
cleavage activity of these enzymes is conferred by the β-site APP cleaving enzyme 1 (BACE1) 
and Presenilins (PSENs) catalytic domains, respectively. The β-cleavage of APP generates 
the soluble fragment sAPPβ, which is released extracellularly. The cleavage of the remaining 
fragment, C99 (β-CTF), by γ-secretase, generates the Aβ peptide and the APP intracellular 
domain known as the AICD (β-γ) (Nixon 2007; Rajendran & Annaert 2012). Aβ peptides have 
varying lengths, with up to 43 amino-acid sequences. Neurons mostly generate the Aβ40 and 
Aβ42 peptides and healthy neurons have high Aβ40/Aβ42 ratio, whereas AD neurons 





generate more Aβ42 which is thought to have an extremely high propensity to aggregate and 
complicity facilitates plaque formation (Fig 1.11) (Nixon 2007). 
In the alternative non-amyloidogenic pathway, APP is cleaved at the α-site by α-secretase, 
also known as distintegrin or metalloproteinase 10 (ADAM10), to generate the soluble 
fragment sAPPα and the still membrane bound C83 (α-CTF) respectively. C83 is then cleaved 
by γ-secretase to generate the AICD (α-γ) and small peptide called p3 (Fig 1.11) (Nixon 2007; 
Rajendran & Annaert 2012). 
Amyloidogenic processing has been detected preferentially on endosomal membranes, 
whereas non-amyloidogenic processing occurs mainly on the plasma membrane. Intracellular 
Aβ is the suspected source of plaque deposits. In fact, it seems that Aβ rises substantially 
within endo-lysosomal compartments before deposition and remains elevated in the heavily 
plaque infested AD brain. Some AD model studies have even reported cognitive deficits with 
elevated intracellular Aβ levels in the absence of plaque deposition (Nixon 2007). 
 
 
1.4.1 Amyloid Pathology 
The aggregate prone Aβ42 accumulates in cells by arranging into soluble oligomers, insoluble 
fibrils and finally amyloid or “senile” plaques. However, accumulating evidence suggests that 
the oligomers appear to be the main source of its neurotoxicity (Shankar et al. 2008; Shankar 
& Walsh 2009; Li et al. 2009). The mechanisms of the toxicity is broadly linked to synaptic 
damage and cognitive impairment, specifically it is described as a pathological interaction 
Figure 1.11: The APP processing pathway. The amyloidogenic and non-amyloidogenic pathway as 
described. Adapted from Rajendran & Annaert 2012 





between Aβ oligomers and NMDA receptors (Musiek & Holtzman 2015; Li et al. 2009; Shankar 
& Walsh 2009). 
Of note, it has been demonstrated that protein aggregation itself may not be the cause of cell 
death. Arrasate and colleagues have demonstrated that of cells exposed to mutant huntingtin 
protein, the ones containing huntingtin aggregates or protein inclusion bodies survived longer 
than cells containing no aggregates (Arrasate et al. 2004). In fact, some posit that Aβ 
aggregation may be a cellular protective mechanism rather than the cause of cell death (Ross 
& Poirier 2005). 
Aβ oligomers also initiate Tau hyperphosphorylation through aberrant activation of kinases 
such as Fyn (Musiek & Holtzman 2015). Although a causal link between Aβ pathology and 
Tau hyperphosphorylation has been elucidated, the exact molecular cascade is vastly 
complex (Zempel et al. 2013; Musiek & Holtzman 2015).  
Furthermore, a landmark review published by R. Nixon (2007) summarized the role that 
autophagy and endocytosis played in the turn-over of APP-rich organelles and subsequent 
generation of Aβ. It highlighted the fact that a combination of increased autophagy induction 
and defective clearance of Aβ-generating vacuoles play a pivotal role for Aβ accumulation in 
AD (Nixon 2007). 
 
1.5 Mitochondrial dynamics 
Tubulin functionality and the autophagy machinery are both intricately linked to mitochondrial 
function, quality control and transport. Although not a major theme of this review, the 
connection between microtubulin, autophagy and mitochondrial dynamics deserves attention, 
due to the role it plays in cell death onset. 
Neurons are highly dependent on mitochondrial-derived ATP due their low anaerobic capacity 
and high energetic demand. ATP availability needs to be kept constant for normal cellular 
maintenance and growth. Mitochondria differ from each other depending on subcellular 
compartmental localisation (DuBoff et al. 2013). Neuronal mitochondria can be distinguished 
into two groups, synaptic and non-synaptic. These two groups differ in size, trafficking patterns 
and function (DuBoff et al. 2013). To maintain the high energy demand of synaptic 
transduction, synaptic mitochondria are larger and longer-lived, rendering them susceptible to 
accumulating damage (DuBoff et al. 2013). 
Mitochondria are compartmentalised double membrane organelles that provide ATP to the 
cell through oxidative phosphorylation. Oxidative phosphorylation relies on the electron 
transport chain (ETC), located on the inner membrane of the mitochondria and is composed 





of four biochemically linked complexes (I, II, III and IV) and two electron carriers (CoQ and 
CytC) (DuBoff et al. 2013). Mitochondria utilize cytosolic nutrient stores to produce ATP 
through an electrochemical gradient generated by the ETC across the membrane. 
Additionally, mitochondria are also the main producers of reactive oxygen species (ROS) 
(DuBoff et al. 2013). ROS have physiological functions under normal conditions, but are prone 
to contributing to pathological conditions when excessively produced. High levels of ROS 
induce lipid peroxidation, as well as DNA, mtDNA and ETC damage. To combat the damaging 
effects of ROS, mitochondria have an underlying quality control system for removing damaged 
mitochondria through fission-mediated mitochondrial autophagy (known as mitophagy) and 
rely on inherent anti-oxidant systems (DuBoff et al., 2013). 
Mitochondria are maintained as short tubular structures that are highly dynamic - a property 
that is modulated through fission and fusion. Fission and fusion establish mitochondrial shape 
and size and allows for the sharing of proteins, lipids and DNA (Itoh et al. 2013). The sharing 
of contents, through fusion, acts as a compensatory mechanism; by which dysfunction is 
transiently buffered. Fission allows for the transport and distribution of damaged mitochondria. 
Fission and fusion dynamics are mediated through dynamin related proteins (DRPs). DRPs 
belong to the GTPase family, which are dependent on GTP hydrolysis for self-assembly and 
subsequent modulatory effects (Itoh et al., 2013; DuBoff et al., 2013). 
During fission, Drp1 assembles into helical structures that wrap around mitochondria and 
scissions it into two daughter mitochondria that differ energetically, with one being 
hyperpolarised and the other depolarised. Depolarised mitochondria are less likely to fuse and 
are more susceptible to mitophagy, but depolarisation alone is insufficient to induce this 
particular state (Itoh et al. 2013). During fusion, mitofusins 1 and 2 (Mfn1 and Mfn2), located 
on the outer membranes of adjacent mitochondria, dimerise and facilitate outer membrane 
fusion. Inner membrane fusion is then facilitated by OPA1 (optic atrophy 1), located in the 
inter-membrane space. Functional fission and fusion is essential for cellular homeostasis (Itoh 
et al. 2013). 
The fission of mitochondria also allows for mitophagy, through which damaged or depolarised 
mitochondria are degraded. Mitophagy is controlled through the action of the two proteins 
called PINK1, a serine/threonine kinase located on the mitochondrial membrane, and Parkin, 
a ubiquinating E3 type ligase. In healthy mitochondria, PINK1 concentrations are kept low by 
membrane potential-dependent recruitment and proteolytic cleavage (Yan et al. 2013). 
However, damaged or depolarised mitochondria cause PINK1 accumulation that signals 
recruitment of Parkin, which subsequently ubiquinates the mitochondria and targets it for 
mitophagy (Yan et al. 2013). Mutations in both PINK1 and Parkin are the cause of the 
neurodegenerative disease autosomal recessive juvenile parkisonism (Yan et al. 2013). 





Other than their importance in maintaining cell viability through preserving metabolic activity, 
rather contrastingly, mitochondria also play a major role in the control of cell death, specifically 
apoptotic cell death (discussed further in 1.6), which is a major cell death modality in 
neurodegeneration. 
 
1.6 Mechanisms of cell death 
Apoptotic neuronal cell death is a hallmark feature of both aging and neurodegenerative 
disease (Gorman 2008). Although neuronal cell death is recognised as a major part of 
neurodegenerative pathologies, it is not always clear how this occurs. Multiple modes of cell 
death have been elucidated in the last few decades in addition to apoptosis, which include 
necrosis and a third mode, termed autophagic cell death (ACD). ACD is still considered very 
a highly controversial “mode” of cell death because it is rarely witnessed and so far has only 
been observed to occur in Drosophila salivary glands, therefore it shares no relevance to 
neurodegeneration (Baehrecke, 2003). 
 
1.6.1 Apoptosis  
Apoptosis is the tightly regulated, energy-dependent and gene-controlled process of 
programmed cell death. It is morphologically characterised by pyknosis (nuclear 
condensation) and karyorrhexis (nuclear fragmentation), membrane blebbing and the 
separation of internal structures into apoptotic bodies (Loos et al. 2013). Physiologically 
appropriate neuronal apoptosis is crucial in normal neurodevelopment, specifically during 
neurogenesis (Becker & Bonni 2004; Cavallaro 2015). The activation of a family of proteases 
called caspases, play a centralised role in controlling apoptotic activity and act through mainly 
two distinct pathways; namely the intrinsic and extrinsic pathways. These two pathways differ 
in the initiation of the apoptotic cascade, but converge on the same execution phase that 
completes the mechanisms leading to cell death (Elmore 2007). These pathways are briefly 
summarised as follows: 
 
1.6.1.1 Intrinsic/Mitochondrial Pathway 
The intrinsic or mitochondrial pathway is, as suggested by the name, mitochondria-dependent. 
It is activated by non-receptor mediated stimuli that can be divided into positive and negative 
signals. Negative signals include, but are not limited to, the withdrawal of certain hormones or 





growth factors. Positive signals can be external stressors such as hypoxia or extreme 
temperatures (Elmore 2007). 
These stimuli cause a change in the mitochondrial inner membrane, which leads to the 
opening of the mitochondrial permeability pore (MTP). MTP opening leads to a loss in 
membrane potential and the release of two main groups of pro-apoptotic proteins. The first 
group of proteins include cytochrome-c, which causes the recruitment of Apaf-1 and 
procaspase-9 into a structure called an apoptosome. The apoptosome allows auto-activation 
of the initiator caspase-9 that subsequently cleaves procaspase-3 and activates the execution 
phase. Along with cytochrome c, AIF release takes place and causes DNA damage in a 
caspase-independent manner. The second group of proteins released are the Smac/DIABLO 
complexes that are thought to initiate apoptosis by removing the inhibitory effect of IAPs 
(inhibitory apoptotic proteins) (Elmore 2007; Gorman 2008).  
The regulation of these mitochondrial events occurs through the actions of the Bcl-2 family of 
proteins, which include anti-apoptotic proteins such as Bcl-2 and Bcl-x, and pro-apoptotic 
proteins such as Bid, Bax and Bad (Elmore 2007). The executioner phase is initiated by the 
cleavage of procaspase 3 into caspase-3, also known as an “executioner caspase”. Caspase-
3 cleaves cytoskeletal proteins and translocates to the nucleus, where it cleaves the nuclear 
material, eventually causing DNA damage and chromatin condensation. At the same time, 
caspase-3 also cleaves Poly (ADP-ribose) Polymerase (PARP), a DNA repair enzyme, to 
prevent DNA recovery – ultimately committing the cell to death (Elmore 2007).  
 
1.6.1.2 Extrinsic/Death Receptor Pathway 
The extrinsic pathway is activated by transmembrane receptor-mediated interactions of 
specific ligand binding. These ligands include amongst others, FasL and TNF-α, and their 
respective receptors, FasR and TNFR1. Ligand binding causes trimerisation of the receptor 
complexes and recruitment of cytoplasmic adaptor proteins with corresponding so called 
“death domains”, i.e FADD and TRADD. The adaptor proteins dimerize with pro-caspase 8, 
and subsequently leads to auto-activation which generates caspase-8 that cleaves 
procaspase 3 into caspase-3 and initiates the execution phase (Elmore 2007).  
Ccaspase-8 has been shown to cleave the pro-apoptotic protein Bid into a tBid fragment, 
which subsequently leads to MTP opening and the initiation of the intrinsic pathway. This is a 
prime example of cross talk between pathways and clearly indicates that they do not 
necessarily operate in a mutually exclusive fashion (Kermer et al. 2004; Gorman 2008). 






Necrosis is a non-programmed, energy-independent and acute form of cell death. It is 
morphologically characterised by a rapid loss of membrane integrity with consequent lysis and 
release of cell constituents into neighbouring tissue. This leads to the release of pro-
inflammatory cytokines and the subsequent destruction of neighbouring cells. Necrosis is 
usually the result of severe stress, i.e direct trauma or toxin exposure. It does not have a clear 
biochemical pathway of induction and thus remains a difficult mode of cell death to fully 
characterise, let alone modulate (Gorman 2008; Loos et al. 2013). 
 
1.6.3 Excitotoxic Cell Death 
Although it is debated whether Excitotoxic Cell Death (ECD) is a true “mode of cell death” it 
has a significant role to play in the neuron loss witnessed in late AD. Briefly, excitotoxicity is 
defined as “a toxic process characterized by a sustained stimulation of excitatory amino acid 
receptors mainly involving N-methyl-D- aspartate Receptors (NMDARs)” (Kamat et al. 2016). 
ECD generally occurs as a result of ATP-depletion during a periods of ischemia (Kamat et al. 
2016). The ATP loss causes depolarisation of neurons, which stimulates neurotransmitter 
release and failure of ATP-dependent neurotransmitter re-uptake transporters. Glutamate is 
the most abundant excitatory neurotransmitter in the brain and its aberrant release causes 
overstimulation of ion-gated NMDARs. This results in an influx of Ca2+ ions that can cause 
both ER and mitochondrial stress – ultimately leading to the onset of cell death (Gorman 2008; 
Kamat et al. 2016). Whether it exclusively causes either necrotic or apoptotic cell death 
remains unclear, but this seems to be dependent on general mitochondrial health (Ankarcrona 
et al. 1995) 
In AD, exictotoxicity is hypothesized to occur in a “slow” tonic rather than phasic manner. 
Functional MRI studies in patients with prodromal AD revealed an increase in neural network 
activity relative to baseline, rather than a loss of activity (Putcha et al. 2011). Ong and 
colleagues suggest that this may be a compensatory mechanism by the brain to cope with 
early neuronal loss (Ong et al. 2013). The abundance of cell death witnessed in late disease 
correlates with symptom onset, which warrants earlier therapeutic interventions. 
 





1.7 Summary of pathophysiology 
Figure 1.12: Schematic summary of AD pathophysiology in context.  Schematic summary summarising the complex pathological changes that manifest in 
the aetiology of Alzheimer’s disease 
Stellenbosch University  https://scholar.sun.ac.za





1.8 Current and potential treatment modalities 
Multiple treatments have been developed over the years, ranging from anti-Aβ vaccines to 
diet modulation. However, there has been limited or no success. AD progresses in a 
somewhat coordinated manner in terms of spatiotemporal brain degeneration. The disease 
usually affects the hippocampus first and this occurs in the prodromal stage. Eventually this 
pathology manifests in the cortex during late disease. Braak and Braak were the first to 
elucidate these macroscopic changes into stages (see original review (Braak et al. 1994)), 
which demonstrates that particular neuron populations are lost in specific brain regions and 
can be attributed to phenotypic characteristics of the pathophysiology. Acetylcholine (ACh) 
secreting neurons are one such group of neurons that are lost early in the AD pathophysiology 
(Tiernan et al. 2016). The “cholinergic deficit hypothesis” postulates that many symptoms of 
dementia, such as behavioural and LTP (Long Term Potentiation) deficits, can be attributed 
to the substantial loss of cholinergic neurons and ACh (Auld et al. 2002). As such, many drugs 
were developed to treat this part of the pathology with the aim to improve ACh concentrations 
by inhibiting cholinesterase activity (Godyn et al. 2016). 
Multiple clinical trials and drug development trials targeting AD and dementia-related disorders 
are initiated every year. There are currently more than 200 clinical trials in various stages of 
progress within this research area. Listed in the tables below are select past and present 
potential candidate drugs that highlight the complexity of the disease and the many molecular 
targets, of special focus are those targeting Tau pathology. 
Table 1.1:  Available Pharmacological Interventions 
Drug Target Disease Stage Target 
Tacrine Acetylcholinesterase 
inhibitor 
Mild to Moderate 
Rivastigmine Acetylcholinesterase & 
butyrylcholinesterase 
inhibitor 
Mild to Moderate 
Galantamine Acetylcholinesterase 
inhibitor 
Mild to Moderate 
Donepezil Acetylcholinesterase 
inhibitor 
Mild to Moderate 
Memenatine NMDA agonist Mild to Moderate 
 





Table 1.2: Select pharmacological Interventions currently in Clinical Trials – highliited in grey are drugs 
targeting Tau pathology and autophagy. Partially adapted from Godyn et al. 2016. 




Country/Region  Clinical Trial 
Reference 



































AZD 3293 β-Secretase inhibitor Early-Late Phase 
II/III 
World Wide NCT02245737 








World Wide NCT01767311 
























World Wide NCT01723826 















World Wide NCT01224106 









World Wide NCT02079246 
Intranasal Insulin GSK-3β inhibitor Early Phase 
II 
US NCT02503501 























World Wide NCT01900665 













Although many of the available and potential drugs seem very promising in targeting what are 
considered “hallmark” pathologies of AD, none have had any reasonable success thus far. 
Also, none target proteostatic dysfunction, which has been shown to occur prior to these 
perturbations. 
Lastly, no mechanisms have been elucidated to explain a potential link between proteostatic 
failure and downstream pathologies such as Tau dissociation and the associated microtubulin 
instability. Investigating a potential and novel relationship between these pathologies may 
reveal a novel therapeutic intervention in prodromal Alzheimer’s disease, which may delay or 
even halt the disease onset. This topic shall be the focus of this study. 
  





1.9 Problem statement 
The underlying mechanisms that govern Tau aggregation and subsequent microtubulin 
instability are neither fully understood nor characterized in current literature. In addition, it is 
not known to what extent autophagy dysfunction influences the pathological changes 
associated with microtubule destabilisation, Tau aggregation and proteotoxicity. 
 
1.10 Hypothesis  
Due to the dynamic nature of the MT, and the rapid turnover of the tubulin pools, a constituent 
basal level of Tau degradation is required. We thus hypothesize that autophagy disruption 
causes Tau to accumulate intracellularly, and in particular along the microtubulin network. 
Accumulated Tau associated with the microtubule becomes hyperphosphorylated, reducing 
its binding affinity and ultimately causing its dissociation. This in turn will increase microtubule 
susceptibility to severing enzymes such as Spastin and Katanin, causing its fragmentation and 
dysfunction. It is further hypothesized that these events occur prior to the onset of cell death. 
 
1.11 Aims 
The aims of this study were therefore to investigate the effects of autophagy perturbation on 
Tau and microtubulin dynamics in an in vitro model by: 
I. Establishing two time points of autophagy inhibition. The first being an early time point at 
which the perturbation does not negatively impact cell viability, and a second time point at 
which the perturbation induces cell death in order to assess any changes in parameters of 
microtubule network functionality prior to the onset of cell death. 
II. Assessing Tau protein dynamics in relation to its phosphorylation state and localisation 
with the microtubule network. 
III. Assessing microtubulin stability and ultrastructure under autophagy inhibition by utilising 
Super Resolution microscopy techniques. 
IV. Assessing the effect of chloroquine treatment on the relative autophagic flux of the system 
 
  





Chapter 2: Materials and Methods 
2.1 Reagents and Consumables 
2.1.1  Cell Lines and General Cell Culture Reagents 
Murine hypothalamus-derived GT1-7 neuronal cells were a kind gift from Prof Pamela Mellon 
(University of California, San Diego, USA) (Mellon et al. 1990). Dulbecco’s Modified Eagles 
Medium (DMEM) (41965-039), Penicillin-Streptomycin (PenStrep) (151140-122), 0.25% 
Trypsin-EDTA (25200-072) and NUNC™ Lab-Tek™ II Chamber Slide™ 8-chamber dishes 
(154534) were purchased from ThermoFisher Scientific (TFS). Foetal Bovine Serum (FBS) 
(FBS-GI-12A) was purchased from CAPRICORN® Scientific. T25 (25 cm2) (Nest®, 707001), 
T75 (75 cm2) (Nest®, 708001), T175 (175 cm2) (Nest®, 709001), 6- (Nest®, 703001), 48- (SPL®) 
culture flasks and plates were purchased from BiocomBiotech (South Africa).  
 
2.1.2  Treatment and Experimental Reagents 
Chloroquine diphosphate salt (C6628), WST-1 Cell Proliferative Reagent (11644807001) and 
2-Cysteamine (M9768) were purchased from Sigma-Aldrich. Bafilomycin A1 (B0025) was 
purchased from Lkt® Labs. 
 
2.1.3 Antibodies and Plasmid Constructs 
2.1.3.1 Primary Antibodies 
Primary antibodies that were used, in some cases for both immuno-fluorescent labelling and 
Western blots, include anti- acetylated α-tubulin, anti-CP27 (Tau) (a kind gift from Prof Peter 
Davies (Albert Einstein College of Medicine, Bronx, New York)), anti-Katanin p60, anti-LC3B, 
anti-p62, Anti-pTau, anti-Spastin and anti-β-actin.  
Table 2.1: The respective information of primary antibodies utilised. IF – Immunofluorescence Microscopy; 












Mouse Anti-Mouse 55 kDa 1 μL:1000 μL 1 μL:200 μL 
Anti-CP27 (Tau) N/A Mouse Anti-Mouse 50 kDa 1 μL:1000 μL N/A 
Anti-Katanin P60 Santa Cruz 
(109299) 
Goat Anti-Mouse 60 kDa 1 μL:1000 μL 1 μL:200 μL 
Anti-LC3B CST (2775) Rabbit Anti-Mouse 14-16 kDa 1 μL:5000 μL N/A 







Rabbit Anti-Mouse 62 kDa 1 μL:5000 μL N/A 
Anti-pTau 
(S400/T403/S404) 
CST (11837) Rabbit Anti-Mouse 50-80 kDa 1 μL:5000 μL 1 μL:100 μL 
Anti-Spastin Abcam 
(10197) 
Rabbit Anti-Mouse 64-68 kDa 1 μL:5000 μL 1 μL:100 μL 
 
2.1.3.2 Fluorescent probes and HRP-linked Secondary Antibodies 
The following fluorescent probes and Horse Radish Peroxidase (HRP) - linked secondary 
antibodies were used for microscopy and Western blot analysis, respectively. 
Table 2.2: The respective information of secondary antibodies utilised. IF – Immunofluorescence Microscopy; 
WB – Western blot 
Probe Company/ 
Cat# 
Animal Source/Target WB Dilution IF Dilution 
Alexa Fluor 488 ThermoFisher (A-21202) Donkey Anti-Mouse N/A 1 μL:200 μL 
Alexa Fluor 568 ThermoFisher (A-10042) Donkey Anti-Rabbit N/A 1 μL:200 μL 
Alexa Fluor 568 ThermoFisher (A-11057) Donkey Anti-Goat N/A 1 μL:200 μL 
HRP Abcam (97110) Donkey Anti-Goat 1 μL:20 000 μL N/A 
HRP CST (7074) Goat Anti-Rabbit 1 μL:10 000 μL N/A 
HRP CST (7076) Anti-Mouse 1 μL:10 000 μL N/A 
 
2.1.3.3 Transfection Reagents and DNA constructs 
GT1-7 cells were transfected with the Tau plasmid construct using the NEON® Electroporation 
Transfection System and NEON® Transfection Kit, according to the manufacturer’s protocol. 
The pRK5-EGFP-Tau P301L (Human Tau) (#46908) construct was purchased from 
AddGene®. 
 
2.1.4 Protein determination and Western Blot Reagents 
Bradford Reagent (B6916) and Bovine Serum Albumin (BSA) (B8894) was purchased from 
Sigma-Aldrich. 12% Fast-Cast® Stain-free® SDS-PAGE gel casting kit (1610184), 0.2 µm 
polyvinylidine fluoride (PVDF) Midi Trans-Blot Turbo Transfer Packs (170-4157) and Clarity® 
ECL (Enhanced chemiluminescence) peroxide reagent kit (1705061) were purchased from 
BioRad (South Africa). 
 





2.2 Experimental Procedures 
2.2.1 Tissue Culture of GT1-7 cells 
Cells were cultured in DMEM supplemented with 10% FBS and 1% PenStrep, and maintained 
in a humidified incubator (Snijders Scientific, C01901) at 37 ⁰C and 5% CO2 atmosphere. 
 
2.2.1.1 Thawing and Culturing of Cells 
Cryovials containing approximately 1x106 cells in 1 mL FBS, with 10% DMSO, were thawed 
in 37 ⁰C warm water. The suspension was then slowly added to 4 mL pre-warmed media in a 
15 mL falcon tube. The contents were spun down in a centrifuge (Eppendorf, 5804) for 4 min 
at 1500xg. The supernatant was discarded to remove DMSO and the pellet was resuspended 
in warm media and subsequently added to a T25 culture flask containing 5 mL fresh media. 
The media was changed every 2-3 days until the desired confluency (70-80%) was reached, 
after which cells were subcultured and seeded for experimental conditions indicated. 
 
2.2.1.2 Sub-culturing of cells for Experiments 
For passaging and sub-culturing of cells, media was removed and the cell monolayer was 
briefly rinsed with 1mL 0.25% trypsin-EDTA as recommended by ATCC. Once the initial 
trypsin was removed, 4 mL of fresh trypsin was added and left to incubate for 5 min until cells 
loosened. The trypsin was neutralised with FBS containing DMEM (2x volume of trypsin). The 
suspension was then centrifuged for 4 min at 1500 xg. The pellet was resuspended and cells 
were counted in a Neubauer Improved haemocytometer (Marenfield) to be seeded for various 
experiments. 
 
2.2.1.3 Experimental Groups 
To induce and determine autophagic dysfunctional states, as detailed in the experimental 
aims, GT1-7 cells were treated with the lysomotrophic reagent chloroquine diphosphate (CQ) 
with varying concentrations (ranging from 12.5 to 100 μM) for 6 and 24 h, respectively. Viability 
of cells was then determined using the WST-1 assay. The concentration that caused a 
significant decrease in cell viability after 24h, but not 6h, was selected for subsequent 
experiments. 
For Western blot analysis, cell lysates were harvested every 2h over a period of 24h. In 
addition, select time points within the 24h period were chosen and treated with Bafilomycin A1 





for 2 hours post chloroquine treatment to measure relative autophagic flux. These selected 
time points included 6h and 24h. 
 
2.2.2 Reductive Capacity Assay 
A WST-1 assay was used to measure the cellular reductive capacity in response to the 
chloroquine treatment. It has historically been used as a marker for cell viability in numerous 
studies by inferring cell death due to a lack of metabolic activity (Gomez et al., 1997; Goodwin 
et al., 1995). WST-1 is a tetrazolium-based salt that is reduced by primarily mitochondrial 
enzymes into water-soluble formazan crystals. The media containing the dissolved crystals 
can then be measured spectrophotometrically and viability be inferred. 
In brief, GT1-7 cells were seeded into a 48-well plate at a density of 75 000 cells/well and left 
to grow in 200 μL media overnight. The following day, cells were treated over the required 
time period. Next, 10 μL of WST-1 reagent was added to each well and plates were incubated 
for a period of 2 hours, after which they were agitated in a shaking incubator (37 ⁰C, 200 RPM) 
for 5 min to dissolve the formazan crystals. Supernatants were spectrophotometrically read at 
a wavelength of 595 nm on a universal micro plate reader (EL800, Bio-Tek Instruments Inc.) 
and data were recorded using the KC Junior software. Absorbance values were expressed as 
a percentage of the control ± SEM.  
 
2.2.3 Protein Determination 
Once treatment protocols were completed, media was removed from T75 culture flasks, cells 
were immediately placed on ice and thoroughly washed 3x with cold PBS. Total protein of 
GT1-7 cells was extracted with a radio-immunoprecipitation (RIPA) lysis buffer containing Tris-
HCl 50 mM; NaCl 150 mM, EDTA 1 mM, NP-40 1%, Na-deoxycholate 0.25%. The buffer was 
supplemented with 1 mM Sodium Orthovanadate (Na3VO4), 1 mM Sodium Fluoride (NaF), 1 
mM PMSF (phenylmethylsulfonyl fluoride) and  1x cOmplete Protease Inhibitor Cocktail (as 
per manufacturers protocol), to inhibit both phosphatase and protease activity. 
Protein content of GT1-7 cell lysates was quantified using the Bradford Reagent assay 
(Bradford, 1976). 
 
2.2.4 Sample Preparation 
Samples were prepared after protein content of lysates had been determined. Aliquots 
containing 50 μg/ μL of protein and Laemli’s sample buffer (diluted in a 2:1 ratio) were 





prepared. The aliquots were stored at -80 ⁰C and thawed when required. Prior to loading onto 
the gels, samples were thawed on ice and boiled at 95 ⁰C for 5 min to denature and linearize 
proteins.  
 
2.2.5 SDS-PAGE and Western Blot Analysis 
GT1-7 were added to wells of a 10-well 1 mm casted gel using a 12% Stain-free® Fast-Cast® 
SDS-PAGE kit. Proteins were separated using 250 V and 400 mA for an average time of 90 
minutes. Once the electrophoresis was complete, proteins were transferred to a PVDF 
membrane using a Trans-Blot Transfer pack (GT1-7 cells) using the BioRad Trans-Blot Turbo 
electrotransfer system (BioRad, 170-4155), which is operated at 120V and 400mA for 7 
minutes. The membrane was then incubated for 1 hour in 5% fat-free milk made up in Tris-
buffered saline/0.1% Tween 20 (TBS-T) to prevent non-specific binding. Once the blocking 
procedure was complete, membranes were washed 3x 5 min with TBS-T and subjected to 
probing with the specific primary antibody at 4°C overnight. The following day, membranes 
were washed 3x 5 min with TBS-T and probed for 1 hour at room temperature with the 
corresponding secondary antibody. Membranes were washed 3x 5 min with TBS-T and 
exposed to ECL chemiluminescent reagent for 5 minutes. Developing bands were detected 
and captured using the ChemiDoc imaging system (ChemiDoc MP, Imaging System). Band 
intensities were normalised against total lane protein and quantified using the Bio-Rad Image 
Lab software.  
 
2.2.5.1 Total Protein Loading Controls 
BioRad Stain-free® technology allows for the normalisation of band intensities to total protein 
in respective lanes, which is due to a patented additive within the gel mixture (BioRad 2014). 
The additive reacts with tryptophan residues within protein sequences and allows their 
visualisation when exposed UV radiation. The Bio-Rad Image Lab software provides a user 
friendly interface to generate normalised data.   
 
2.2.6 Transfection optimisation 
An established protocol for optimised transfections in the GT1-7 cell line was used. This 
allowed for the highest transfection efficiency and cell viability after the electroporation 
process.  





In brief, 500 000 cells were trypsinsed, counted and washed in PBS. Next, after being spun 
down the PBS was decanted and cells resuspended in 100 μL sterile Neon® Resuspension 
buffer containing 5 μg of GFP-Tau (P301L) DNA. Next, the suspension was aspirated into a 
gold plated Neon® Tip using a Neon® Pipette. The tip was then immersed into Neon® 
Electrolytic buffer inside the Neon® Pipette Station, and cells were electroporated at 1350 V 
for 1 pulse lasting 30 ms. Finally, cells were plated into 6-well dishes containing 14 mm round 
coverslips in fresh media without antibiotics and left to recover overnight. Following the 
recovery period cells were treated as required. 
 
2.2.7 Confocal and SR-SIM Fluorescent Microscopy 
2.2.7.1 Sample Preparation for SR-SIM and Confocal microscopy 
In brief, 50 000 transfected or untransfected cells were seeded into 6-well dishes containing 5 
mm round coverslips and 2 mL fresh media and left to grow overnight. The next day coverslips 
were treated according to the previously determined experimental groups. Once treatment 
had completed cells were fixed for 10 min in a 1:1 ratio of 4% w/v Paraformaldehyde: DMEM 
at 37⁰C in an incubator. Coverslips were then washed 3x 5 min with cold PBS, after which 
they were incubated for 30 min in a blocking buffer made up of 5% v/v donkey serum in PBS. 
After blocking, cells were subjected to the required primary antibodies, and incubated 
overnight at 4 ⁰C. The following day cells were probed with corresponding secondary 
antibodies for 50 min, after which 50 uL of diluted Hoechst 33342 nuclear dye was added. 
Cells were then incubated in the secondary antibody/Hoechst mixture for a further 10 min. The 
coverslips were then washed 3x 5 min with PBS. After the last wash, PBS was decanted and 
slides mounted in an inverted manner onto a glass slide containing Dako® fluorescent 
mounting media and sealed with clear nail polish. Slides were then stored in a foil wrapped 
container at -20 ⁰C until analysis was required.  
 
2.2.7.2 Confocal microscopy sample acquisition and processing 
Confocal analysis was performed on fluorescently stained and transfected cells using the 
Zeiss LSM 780 system (Carl Zeiss Microimaging, Germany). Data of cells were collected by 
acquiring z-stacks, each with 10-12 image frames, and increments of ~0,975 μm step width. 
A LCI Plan-Apochromat 63x/1.4 Oil DIC M27 objective equipped with a Diode 405nm CW/PS 
(pulsed), 488 nm laser, 561 nm laser and GaAsP detector (32+2 PMT), was utilised. 
Maximum intensity projections of z-stacks were processed and generated in the Zeiss Zen 
Black Software (2012) and utilised for subsequent experimental analysis. 





2.2.7.3 SR-SIM microscopy sample acquisition and processing 
For SR-SIM analysis of GFP-Tau transfected cells, thin (0.1 μm) z-stacks of high-resolution 
image frames were collected by utilizing an alpha Plan-Apochromat 60x/1.4 oil immersion DIC 
M27 ELYRA objective, using an ELYRA PS.1 system (Carl Zeiss Microimaging, Germany) 
equipped with a 488nm laser (100mW) in 5 rotations, 561nm laser (100mW) in 5 rotations and 
an Andor EM-CCD camera (iXon DU 885). Images were reconstructed using Zeiss Zen Black 
Software (2012) based on a structured illumination algorithm (Heintzmann & Cremer 1999). 
Analysis was performed on reconstructed super- resolution images in ZEN. 
 
2.2.7.4 Co-localisation Analysis 
 Before co-localisation analysis was performed, single stains of cells using each primary 
antibody and its corresponding fluorescently tagged secondary antibody were imaged and 
pixel intensities were viewed on a scatter plot. The scatter plot was defined and generated by 
the Zeiss Zen Lite Black Edition Software (2012) as follows; 
“All pixels having the same positions in both images are considered a pair. Of every pair of 
pixels (P1, P2) from the two source images, the intensity level of pixel P1 is interpreted as X 
coordinate, and that of pixel P2 as Y coordinate of the scatter diagram. The value of the pixel 
thus addressed is increased by one every time, up to the maximum number of pixels used. 
This way, each pixel of the scatter diagram is a value that shows how often a particular pair of 
pixels has occurred” (Zeiss Zen Black Edition Software, 2012). 
Here, P1 and P2 represent two different colour channels captured on the same image. The 
single stains of the two separate fluorophores being analysed for co-localisation are 
represented by the X and Y axis respectively with the intensity of each of the pixels 
representing the value in the respective axis. The single stains allowed for the generation of 
threshold values to prevent a false positive reading when co-localisation analysis was 
performed on an image containing both the fluorophores. Furthermore, a colour lookup table 
at the bottom of the scatter plot indicates the frequency at which pixels occur in the same 
position. 
Two different co-localisation coefficients were calculated using the Zeiss Zen Lite Black Edition 
Software. The calculated coefficients include the Manders’ Overlap Coefficient (MOC) and the 
co-localisation coefficient. 
  





The MOC is mathematically defined as: 
𝑀𝑂𝐶 =
∑ 𝐶ℎ1𝑖 ∗ 𝐶ℎ2𝑖𝑖
√∑ (𝐶ℎ1𝑖)
2




The MOC is a parameter used to quantify co-localisation in image pairs, i.e. two different 
colour channels of the same image. It is insensitive to differences in intensities between the 
two channels, photo-bleaching or signal amplifier settings. The values range from 0 – 1 (0: no 
co-localisation, 1: all pixels co-localise). 








The C1 and C2 coefficients denote the relative number of co-localising pixels in channels 1 
and 2 respectively, as percentage of the total number of pixels above threshold (Zeiss Zen 
Black Software, 2011). It indicates how much of each co-localising fluorophore or protein is 
represented relative to the total number of pixels.  
 
2.2.7.5 Line Profile Intensities 
Line Profile Intensities can be defined as the intensity profiles of two fluorescent molecules as 
determined by a straight line through the region of interest. This allows to elucidate a 
relationship between two labelled proteins, further supporting the extent of co-localisation data 
(Kleemann et al. 2014). The line profiles of the specified proteins were determined using Zeiss 
Zen Lite Black Edition Software (2012) (Kleemann et al. 2014). 
 
2.2.8 STORM 
Stochastic optical reconstruction microscopy (dSTORM) is a super resolution microscopy 
technique that allows the obtaining of fluorescent images beyond the diffraction limit. It is an 
extremely powerful technique in that it can resolve images to a resolution of 20 nm compared 
to SR-SIM which is limited to approximately 80 nm in xy resolution. In sharp contrast, confocal 
microscopy achieves an xy resolution of 200 nm. 
 





2.2.8.1 Sample Preparation 
Samples were similarly prepared as described in 2.2.7.1, except that cells were seeded into 
Mattek 35 mm Gridded Coverslip dishes. Furthermore, cells were fixed for a second time in 
4% w/v paraformaldehyde solution post-secondary antibody incubation, and were exposed to 
2 mL of redox buffer made up of 0.1% 2-Cysteamine in dH2O instead of being mounted.  
 
2.2.8.2 Sample Acquisition and Processing 
STORM was performed on a ZEISS LSM780 ELYRA PS1. Super-resolution microscope, 
equipped with an Alpha Plan-Apochromat 100x/1.46 Oil immersion objective, optimised for 
STORM. The 488nm ELYRA laser (100 mW) was used for excitation, while the BP 495-550 / 
LP750 reflector module was selected for emission detection. The microscope is equipped with 
an Andor EM-CCD (iXon DU 897) camera for STORM. The field of view was cropped to 
include only the desired area of interest, allowing the minimum exposure time of 15 ms and 
for each sample, 50 000 frames were recorded. STORM data was processed with the ZEN 
2012 PALM package. For processing overlap was ignored, a mask size of 9 pixels and peak 
intensity to noise ratio of 5 was selected. Post-processing procedures included a drift 
correction.    
 
2.2.9 Correlative Light and Electron Microscopy (CLEM) 
Correlative Light and Electron Microscopy (CLEM) is an extremely powerful technique that 
allows the correlation of fluorescent microscopy image data with electron microscopy 
micrographs for the evaluation of protein localisation in the context of EM derived ultra-
structural detail.  
 
2.2.9.1 Sample Preparation 
Samples were similarly prepared as described in 2.2.7.1. However, after the last PBS wash 
the coverslips were placed on grid and coated with elemental carbon using a carbon coater 
for Scanning Electron Microscope (SEM) analysis. 
 
2.2.9.2 Sample Acquisition and Processing 
The confocal microscopy data were acquired as described in 2.2.7.2. After carbon coating, 
samples were transferred to the Zeiss MERLIN Field Emission Scanning Electron Microscope 





(Carl Zeiss Microimaging, Germany) with Zeiss SmartSEM for data acquisition using the Zeiss 
SE2 detector and further processed for correlation using the Zeiss Zen Black Software (2012). 
 
2.3 Statistical Analysis 
Statistica® 13 software was used for analysis of all generated data sets. Data were tested for 
normality after which the appropriate tests were performed. These included repeated 
measures one-way ANOVAs with Fishers Least Squared Difference (LSD) Post-Hoc tests. A 
p-value < 0.05 compared to the control was considered statistically significant.  
 
  





Chapter 3: Results   
3.1 Chloroquine treatment causes a significant reduction in cell viability 
after 24 hours 
3.1.2 100 μM CQ causes a significant reduction in cell viability after 24 hours of 
exposure, but not after 6 hours  
 
To determine the desired concentration and time of exposure to CQ set out in the experimental 
aims, GT1-7 cells were exposed to increasing concentrations of the drug for 6 and 24 hours 
respectively. WST-1 reductive capacity was then utilised to assess cell viability of the cells at 
each time point and concentration. After 6 hours, reductive capacity initially increased slightly, 
but not significantly, relative to control when exposed to the 12.5 μM of CQ (105.6 ± 1.12%), 
but steadily declined in a dose dependent manner. This is likely an indication for mitochondrial 
stress in response to the treatment, rather than an increase in viability per se. Furthermore, 
no significant reduction in reductive capacity was observed at this time. 
After 24 hours of CQ exposure, a similar trend was observed when reductive capacity initially 
increased relative to control at 12.5 μM of CQ (106.5 ± 0.95%), but steadily declined in a dose 
dependent manner. However, in contrast to the 6 hour time point, a significant reduction in 
reductive capacity relative to control was observed when cells were exposed to 100 μM of CQ 
[(85.35 ± 1.24%) (p<0.005 vs control)] for 24 hours. 
Figure 3.1: WST-1 reductive capacity assay of cells treated with CQ for 6 and 24 hours, respectively. 100 
μM CQ was sufficient to cause a significant reduction in cell viability after 24 hours of CQ exposure, but not after 
6 hours. All data are presented as a percentage of control (Mean± SEM). ** (p-value<0.005 vs control). N=3 
independent experiments. 





Thus, in all subsequent experiments GT1-7 cells were exposed to 100 μM of CQ for 6 and 24 
hours respectively. 
 
3.2 Chloroquine treatment causes progressive autophagy dysfunction 
by inducing autophagosome synthesis and inhibiting 
autophagosome degradation  
3.2.1 LC3-II protein levels significantly and progressively increase in response 
to CQ exposure 
LC3 has two forms, the non-lipidated LC3-I and the lipidated LC3-II, which is incorporated into 
the forming autophagosomal membrane and can be used as a measurement of the 
abundance of autophagosomes within the cell at a given time. One can compare cytosolic 
LC3-II protein levels from cells treated with the autophagy inhibitor Bafilomycin A1 (BAF), 
Total Protein 
Figure 3.2: Western blot analysis of LC3-II protein levels in response to CQ and/or BAF. CQ led to a 
progressive accumulation of LC3-II over time, in the presence and absence of BAF, confirming autophagy 
dysfunction. Band Intensities normalised to total lane protein. All data are presented as a percentage of control 






















which prevents the fusion of autophagosomes and lysosomes, to untreated cells to measure 
the relative autophagic flux of a system – the rate of autophagosome synthesis versus 
degradation (Mizushima & Yoshimori 2007; Rubinsztein et al. 2009). Similarly, one can also 
test the effect of a therapeutic intervention on the relative autophagic flux of a system by simply 
treating cells in the presence or absence of BAF. 
To confirm autophagy dysfunction, Western blot analysis was performed to assess the relative 
protein levels of LC3-II. The progressive accumulation of LC3-II in response to CQ exposure 
confirmed that autophagy was becoming dysfunctional over time (Fig 3.2 & 3.3). 
In addition to CQ, cells were also in some cases exposed to BAF (400nM) for 2 hours post 
treatment to confirm that CQ was indeed causing complete inhibition of autophagosome 
degradation. 
Our results (Fig 3.2) indicate that CQ caused progressive accumulation of LC3-II leading to a 
significant increase after 6 hours [(155.2 ± 17.23%) (p<0.05 vs control)] and 24 hours [(324.8 
± 68.25%) (p<0.0001 vs control)], respectively. When assessing the effect of BAF on the 
control cells in the absence of CQ, we see that there were no significant differences in LC3-II 
protein levels between the control cells (100 ± 30.65%) and cells treated with BAF (107.1 ± 
23.15%), suggesting a very low rate of relative flux under homeostatic conditions (Fig 3.2). 
Similarly after 6 hours, no significant differences were observed in LC3-II accumulation in cells 
treated with CQ (155.2 ± 17.23%) when compared to cells treated with CQ and BAF (171.1 ± 
39.73%) confirming that CQ was indeed causing maximal inhibition of autophagosome 
degradation at the time (Fig 3.2). In addition, it appears that chloroquine not only inhibits 
autophagy at this time of exposure, but also affects the flux by enhancing autophagosome 
synthesis (Rubinsztein et al. 2009). Finally, relative to 6 hours of CQ exposure, there was a 
significant increase (p<0.05) in LC3-II protein levels after 24 hours of CQ treatment as well as 









 LC3-II protein levels significantly increase after 2 hours of CQ exposure relative to 0 hours 
(p<0.05) and progressively and significantly increase (p<0.0001 vs 0 hours)] further over the 
course of 24 hours. 
 
16 kDa LC3-II 
Total Protein 
Figure 3.3: Western blot analysis of LC3-II protein levels in response to CQ-induced autophagy dysfunction over 
the course of 24 hours. The data suggest progressive autophagy dysfunction due to the inhibition of autophagosome 
degradation. Band intensities normalised to total lane protein. All data are presented as a percentage of 0 hours (Mean ± 
SEM). ** (p<0.05 vs 0 hours) *** (p<0.0001 vs 0H). N=3 independent experiments 
 





3.2.2 p62 protein levels significantly and progressively decrease in response 
to CQ exposure 
 
p62 is an autophagy related adaptor protein that targets poly-ubiquinated proteins toward the 
forming autophagosome for selective degradation (Sahani et al. 2014). p62 not only directly 
interacts with LC3 residues but is also independently incorporated into the autophagosomal 
membrane and can therefore also be used as a marker for selective autophagy activity 
(Sahani et al. 2014). Our results (Fig. 3.4) indicate that CQ caused a progressive decline in 
p62 protein levels over time leading to a significant decrease relative to control after 24 hours 
[(48.74 ± 11.93%) (p<0.05 vs control)]. Similarly, a significant decrease was also observed 
between the control cells and cells treated with both CQ and BAF after 24 hours [(36.88 ± 
14.46%) (p<0.0001 vs control)]. In addition, a significant decrease was also observed relative 
to 6 hours of CQ treatment after 24 hours of CQ (p<0.05) as well as CQ and BAF (p<0.05). 
Figure 3.4: Western blot analysis of p62 protein levels in response to CQ and/or BAF. CQ led to a progressive 
decline in p62 concentrations over time. The combined effect of CQ and BAF led to a further decrease in 
concentrations when compared to cells treated with CQ alone, at both 6 and 24 hours of CQ exposure. Band 
Intensities normalised to total lane protein. All data are presented as a percentage of control (Mean ± SEM). * 
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However, no significant differences were observed after 24 hours between cells treated with 
CQ and those treated with CQ and BAF. 
 
3.3 CQ-induced autophagy dysfunction impacts microtubulin stability 
and structure  
3.3.1 Acetylated α-Tubulin protein levels increase non-significantly in 
response to CQ exposure 
 
Acetylated tubulin is considered an indicative marker of stable microtubules (Butler et al. 
2007). Protein levels of acetylated α-tubulin were assessed in response to progressive CQ-
induced autophagy dysfunction. Our results indicate that tubulin stability is impacted over time 
during autophagy dysfunction. Although it is not a trend leading to significance, the progressive 
increase in acetylated tubulin can be observed after both 6 hours (104.3 ± 19.75%) and 24 
hours (125.2 ± 27.86%) of CQ exposure relative to the control (100 ± 22.1%). 
Figure 3.5: Western blot analysis of Acetylated α-tubulin protein levels – a marker for stable tubulin, after 6 
and 24 hours of CQ exposure. CQ-induced autophagy dysfunction led to a non-significant increase in acetylated 
tubulin over time. Band Intensities normalised to total lane protein. All data are presented as a percentage of 
control (Mean ± SEM). N=6 independent experiments 
55 kDa Acetylated 
α tubulin 
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3.3.2 CQ-induced autophagy dysfunction impacts acetylated α-tubulin 
Super Resolution Structured Illumination microscopy (SR-SIM) and direct stochastic optical 
reconstruction microscopy (dSTORM) microscopy are super resolution techniques that 
resolve images to a maximum resolution of 80 nm and 20 nm, respectively. They are thus 
extremely powerful techniques to assess protein localisation and distribution. 
Confocal, SR-SIM and dSTORM microscopy was utilised to assess the acetylated α-tubulin 
signal under control and after CQ-induced autophagy dysfunction. Under control conditions, 
microscopy analysis revealed that acetylated α-tubulin signal was diffusely distributed in the 
cytosol of cells, however, the signal consistently arranged into an intense network like 
morphology in the perinuclear region of the cell (Fig 3.6A, 3.7A & 3.8A). 
After 6 hours of CQ exposure, acetylated α-tubulin became less diffusely distributed in the 
cytosolic compartments and processes, instead arranging into dense filamentous networks 
that distributed the expanse of the cell (Fig 3.6B, 3.7B & 3.8B). 
After 24 hours of CQ exposure, minimal diffusely distributed acetylated α-tubulin signal was 
observed in cytosolic compartments or in processes. The majority of the signal arranged into 
dense filamentous structures in a network morphology (Fig 3.6C, 3.7C & 3.8C). 
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Figure 3.6: Confocal microscopy assessing acetylated α-tubulin signal distribution in response to CQ-induced autophagy dysfunction. Acetylated α-tubulin (Alexa 488) (Green). N=3 
independent experiment. Scale bar = 20 μm and 5 μm, respectively. 
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Figure 3.7: SR-SIM microscopy assessing acetylated α-tubulin signal distribution in response to CQ-induced autophagy dysfunction. Acetylated α-tubulin (Alexa 568) (Red). N=3 
independent experiment. Scale bar = 10 μm and 2 μm, respectively. 
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 Figure 3.8: dSTORM microscopy assessing acetylated α-tubulin signal distribution in response to CQ-induced autophagy dysfunction. Acetylated α-tubulin (Alexa 488) 
(Cyan). N=1 independent experiment. Scale bar = 2 μm and 0,5 μm, respectively. 
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3.4 CQ-induced autophagy dysfunction causes a decrease in Tau 
protein levels and Tau aggregation  
3.4.1 Total Tau protein levels in response to CQ exposure 
 
To assess the protein levels of total Tau in response to the CQ-induced autophagy 
dysfunction, an anti-CP27 antibody was used, which recognises the amino acid sequence 
between the 130-150 residues in human Tau, but also detects mouse total Tau as it shares 
~88% sequence homology (Petry et al. 2014). Our results indicate that Tau is impacted by 
autophagy dysfunction over time as a decreasing trend in protein levels was observed. 
Although the trend is not one leading to significance, we observed progressive decline in total 
Tau protein levels relative to control cells (100 ± 22.29%) at 6 hours (99.36 ± 22.59%) and 24 
hours (83.94 ± 16.55%), respectively.  
 
Figure 3.9: Western blot analysis of total Tau protein levels, after 6 and 24 hours of CQ exposure. CQ-
induced autophagy dysfunction cause a progressive, yet non-significant decrease in Tau protein levels. Band 
Intensities normalised to total lane protein. All data are presented as a percentage of control (Mean ± SEM). N=6 
independent experiments. 
50 kDa Tau 
Total Protein 






Total Tau protein levels declined after 2 hours of exposure to CQ relative to 0 hours, which 
then increased after 10 hours, after which it progressively and gradually decreased during the 
rest of the 24 hour period, relative to 0 hours. Protein levels were significantly reduced relative 




Figure 3.10: Western blot analysis of Tau protein levels in response to CQ-induced autophagy dysfunction over 
the course of 24 hours. Tau protein levels progressively decrease over time in response to CQ exposure. All data are 
presented as a percentage of 0 hours (Mean ± SEM). *(p<0.05 vs 0 hours). N=3 independent experiments. 





3.4.2 Tau progressively aggregates in response to CQ-induced autophagy 
dysfunction 
To assess Tau signal distribution in relation to acetylated α-tubulin in cells, under control and 
experimental conditions, SR-SIM analysis was performed using cells transfected with GFP 
tagged human Tau (P301L) and stained with Alexa Fluor-568 against acetylated α-tubulin (Fig. 
3.11). Under control conditions Tau signal was diffusely distributed within the cell, but 
diminished slightly around the nuclear region (Fig. 3.11A, C &D). Acetylated α-tubulin signal 
was diffusely distributed in the cell cytosol and periphery, particularly the processes, but 
became dense and more ordered around the perinuclear region manifesting as a clear 
microtubulin network pattern (Fig. 3.11B &D). After 6 hours of CQ-induced autophagy 
dysfunction Tau signal became less diffuse, instead arranging into aggregate-like regions in 
the cytosol (Fig. 3.11G & H). Similarly acetylated α-tubulin signal became less diffuse in the 
cytosolic regions, manifesting as highly dense network like microtubule structures (Fig. 3.11F 
&H). Furthermore, clear regions either devoid or with diminished signal were clearly resolved 
in the cytosol (Fig. 3.11H). After 24 hours of CQ-induced autophagy dysfunction, Tau signal 
was maintained in aggregate-like regions (Fig. 3.11K & L), but importantly the aggregated 
signal increasingly concentrated in cell processes (Fig. 20I &L). The acetylated α-tubulin signal 
show clear disruptions in the linear signal distribution (Fig. 3.11L). Moreover, the acetylated 
α-tubulin signal appeared clustered in the peripheral areas of the cell (Fig. 3.11J). 
  







Tau (P301L) Tau (P301L) 
Acetylated α-
tubulin 
Figure 3.11: Distribution of Tau and acetylated α-tubulin signal under control conditions and during various stages of CQ-induced autophagy dysfunction. Blue arrow heads 
indicate vacuole-like structures, white arrow heads indicate tubulin structure and grey arrow heads indicate Tau aggregation. Tau (GFP) and acetylated α-tubulin (Alex Fluor-568). N=3 










































3.5 CQ-induced autophagy dysfunction causes an increase in Tau 
phosphorylation, but not phosphorylated Tau aggregation 
3.5.1 pTau protein levels increase in response to CQ exposure 
 
 
To assess the effect of CQ-induced autophagy dysfunction on Tau phosphorylation we 
assessed phosphorylation at specific sites which included serine 400, threonine 403 and 
serine 404 residues. Tau with phosphorylation of the serine 404 residue has been associated 
with an impaired ability to facilitate microtubule polymerisation (Evans et al. 2000). When 
compared to control (100 ± 24.92%) Tau phosphorylation increased as an early event after 6 
hours (126.4 ± 45.82%) of autophagy dysfunction, although this was not a significant 
difference. Furthermore, this increase in phosphorylation was not maintained after 24 hours 
Figure 3.12: Western blot analysis of phosphorylated Tau (pTau) protein levels, after 6 and 24 hours of CQ 
exposure. CQ-induced autophagy dysfunction caused a non-significant increase in pTau after 6 hours of exposure, 
but this was not maintained after 24 hours. Furthermore, concentrations significantly declined relative to 6 hours 
and non-significantly relative to control conditions. All data are presented as a percentage of control (Mean ± SEM). 
*(p<0.05 vs CON). N=6 independent experiments. 
50 - 80 kDa pTau 





(77.49 ± 32.68%) of dysfunction, as a significant difference between 6 and 24 hours can be 
observed (p<0.05; 6H vs 24H) (Fig 3.12). 
 
 
In response to CQ exposure, phosphorylation of Tau progressively increased, reaching 
significance at 10 hours vs 0 hours (p<0.05) and remained significantly elevated after 16 
hours, but decreased to non-significant levels after 18 hours relative to 0 hours. A non-
significant decreasing trend was observed until 24 hours where the protein levels were 
significantly higher relative to 0 hours (Fig 3.13). 
Although findings of a significant increase in pTau after 24 hours are in contrast to those 
observed in Fig 3.12, it is important to note that the sample size of this particular analysis was 
indeed smaller and therefore the standard error of the mean was larger – reducing the 
statistical power. Nonetheless, the majority of these findings are still in agreement with the 
analysis presented in Fig 3.12, particularly the increase in pTau protein levels observed after 
6 hours of CQ exposure (Fig 3.12 & 3.13). 
 
Total Protein 
pTau 50 - 80 kDa 
Figure 3.13: Western blot analysis of pTau protein levels in response to CQ-induced autophagy dysfunction over 
the course of 24 hours. pTau protein levels progressively increase over time in response to CQ exposure. All data are 
presented as a percentage of 0 hours (Mean ± SEM). *(p<0.05 vs 0 hours). N=3 independent experiments. 





3.5.2 pTau localises within the nucleus, which is maintained during CQ-
induced autophagy dysfunction 
To assess pTau signal distribution in relation to acetylated α-tubulin in cells, under control and 
experimental conditions, confocal analysis was performed using cells stained with Alexa Fluor-
488 against acetylated α-tubulin and Alexa Fluor-568 against pTau, and finally counterstained 
with Hoechst 33342 (Fig. 3.14). pTau signal was distributed very weakly in the cytosol regions. 
In fact, it appeared that the pTau signal was almost exclusively localised within the nucleus 
(Fig. 3.14B & D). After 6 hours of CQ exposure, no changes in of pTau signal distribution were 
observed – as the signal remained concentrated in the nucleus (Fig. 3.14F & H). Importantly, 
no signs of pTau signal aggregation were observed (Fig. 3.14H). After 24 hours of CQ 
exposure, no changes could be discerned in pTau signal relative to the control conditions and 
earlier point of CQ exposure (Fig. 3.14L).Of note, the nuclear signal distribution of pTau 
became progressively more condensed during the CQ-induced autophagy dysfunction 
especially at the late time point (24 hours), which may suggest cellular stress (Fig. 3.14D, H 
& L). Furthermore, the overall cell morphology indicated shrinkage over time and clear 
vacuolar-like structures were observed after 24 hours of autophagy dysfunction (Fig. 3.14L). 
 















Figure 3.14: Distribution of pTau and acetylated α-tubulin signal under control conditions and during various stages of CQ-induced autophagy dysfunction. N=3 independent 
experiments. Acetylated α-tubulin (Alexa Fluor-488), pTau (Alexa Fluor-568) and Hoechst 33342 (Blue). Blue arrow heads indicate vacuole-like structures, white arrow heads indicate tubulin 
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3.6 CQ-induced autophagy dysfunction causes a non-significant 
increase Spastin protein levels and a change in Spastin cellular 
localisation 
3.6.1 Spastin protein levels non-significantly increase in response to CQ 
exposure 
 
CQ-induced autophagy dysfunction led to a progressive increase in Spastin protein levels over 
time. The trend did not lead to a significant increase, but clear differences can be observed 
between control cells (100 ± 24.15%) and those exposed to CQ for 6 hours (120.4 ± 22.12%) 
and 24 hours (132.8 ± 30.59%), respectively.  
 
Figure 3.15: Western blot analysis of Spastin expression, after 6 and 24 hours of CQ exposure. CQ-induced 
autophagy dysfunction caused a progressive, but non-significant increase in Spastin protein levels over time. Band 
Intensities normalised to total lane protein. All data are presented as a percentage of control (Mean ± SEM). N=6 
independent experiments. 
64 - 68 kDa 
Total Protein 
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3.6.2 Spastin signal distributes throughout the cell and forms punctate and 
ordered structures around areas of euchromatin 
To assess Spastin signal distribution in relation to stable microtubulin in cells, under control 
and experimental conditions, confocal analysis was performed using cells stained with Alexa 
Fluor-488 against acetylated α-tubulin and Alexa Fluor-568 against Spastin, counterstained 
with Hoechst 33342 (Fig. 3.16). Spastin signal was diffusely distributed in the cell cytosol, but 
showed strong signal as bright punctate structures around euchromatic DNA regions within 
the nucleus (Fig. 3.16D). After 24 hours of CQ exposure, Spastin signal remained diffusely 
distributed in the cytosol, but the punctate structures around euchromatin regions in the 
nucleus appeared to be reduced in number and intensity (Fig. 3.16H). Furthermore, vacuolar-
like structures with reduced signal distribution were also visible. After 24 hours of CQ 
exposure, the overall cellular morphology showed a decrease in size, indicative of cellular 
stress. Regardless of the size of the cells, clustered acetylated α-tubulin signal could still be 
resolved (Fig. 3.16J & L). Spastin signal remained homogenously distributed in the cytosol, 
but the nuclear puncta were reduced in number, likely due to the nuclear condensation 
observed. Additionally, Spastin signal was observed in the cell periphery, partially extracellular 
area (Fig. 3.16L), suggesting membrane rupture and release of cytosolic constituents. 
 
 






Figure 3.16: Distribution of Spastin and acetylated α-tubulin signal under control conditions and during various stages of CQ-induced autophagy dysfunction. N=3 independent 
experiments. Acetylated α-tubulin (Alexa Fluor-488), Spastin (Alexa Fluor-568) and Hoechst 33342 (Blue). Blue arrow heads indicate vacuole-like structures, white arrow heads indicate 
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3.7 CQ-induced autophagy dysfunction causes a significant increase in 
Katanin p60 protein levels, but no change in Katanin p60 
localisation  
3.7.1 Katanin p60 protein levels progressively and significantly increase in 
response to CQ exposure 
 
CQ-induced autophagy dysfunction led to a progressive increase in Katanin p60 protein levels 
over time. A significant increase in Katanin p60 protein levels was observed after 24 hours 
[(209.4 ± 32.14%) (p<0.05)] of autophagy dysfunction relative to the control conditions (100 ± 
24.03%). After 6 hours (185.1 ± 45.12%) of autophagy dysfunction the Katanin p60 protein 
levels markedly increased relative to the control with a probability strongly leaning towards 
significance (p=0.06). 
  
Figure 3.17: Western blot analysis of Katanin p60 expression, after 6 and 24 hours of CQ exposure. CQ-
induced autophagy dysfunction caused a progressive increase in Katanin p60 protein levels over time, leading to 
a significant increase relative to control after 24 hours of exposure. Band Intensities normalised to total lane protein. 










3.7.2 Katanin p60 signal localised in the nucleus and increased in intensity in 
response to CQ-induced autophagy dysfunction 
To assess Katanin p60 signal distribution in relation to acetylated α-tubulin in cells, under 
control and experimental conditions, confocal analysis was performed on cells stained with 
Alexa Fluor-488 against acetylated α-tubulin and Alexa Fluor-568 against Katanin p60, 
counterstained with Hoechst 33342 (Fig. 3.18). Under control conditions, Katanin p60 signal 
was diffusely distributed across the cell, with random regions containing puncta of intense 
signal. Furthermore, the signal also appeared more intense around euchromatin regions in 
the nuclei (Fig. 3.18D). After 6 hours of CQ, Katanin p60 signal appeared preferentially 
concentrated in areas occupied by euchromatin (Fig. 3.18H). Vacuolar-like structures are 
clearly visible after this time of CQ exposure (Fig. 3.18E). Results after 24 hours of CQ 
exposure remained similar to observed after 6 hours in both acetylated α-tubulin and Katanin 
p60 signal distribution (Fig. 3.18L). Of note, both nuclear and Katanin p60 signal was visible 
outside of the cell, suggesting cell death onset at this stage (Fig. 3.18L). 
 
 






Figure 3.18: Distribution of Katanin p60 and acetylated α-tubulin signal under control conditions and during various stages of CQ-induced autophagy dysfunction. N=3 
independent experiments. Acetylated α-tubulin (Alexa Fluor-488), Katanin p60 (Alexa Fluor-568) and Hoechst 33342 (Blue). Blue arrow heads indicate vacuole-like structures, white arrow 
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3.8 Western Blot Summary Panels  
  Control 6 hour 24 hour 
Figure 3.19: Representative blots of proteins assessed under control conditions and after of CQ exposure. 
Acetylated α-tubulin 55 kDa 
Tau 50 kDa 
pTau 
50 - 80 kDa 
Katanin p60 60 kDa 
Spastin 
64 - 68 kDa 
Total Protein 
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Figure 3.20: Representative blots of proteins assessed over 24 hours of CQ exposure. 
Total Protein 





3.9 CQ-induced autophagy dysfunction causes changes in co-
localisation and line intensity profile intensities between acetylated 
α-microtubulin, microtubule associated proteins and severing 
enzymes   
3.9.1 Tau co-localises with acetylated α-tubulin, which does not significantly 
change during CQ-induced autophagy dysfunction  
3.9.1.1 Line profile intensities of Tau and acetylated α-tubulin 
Line intensity profiles of both Tau and acetylated α-tubulin remained similar in both control 
and CQ-treated conditions. However, regional intensity hot spots of acetylated α-tubulin signal 
were observed in all conditions (Fig. 3.21B, F & J). 
 
3.9.1.2 No significant changes in co-localisation are observed between Tau and 
acetylated α-tubulin 
Manders Overlap Coefficient (MOC) revealed that under control conditions the co-localisation 
between Tau and acetylated α-tubulin signal was very strong with approximately 87% overlap 
between the signals (Table 3.1). Even after 6 and 24 hours of CQ exposure, respectively, the 
values remained near similar, showing a decreasing, but minor, trend over time. This suggests 
no change in co-localisation between Tau and acetylated α-tubulin over time. Under control 
conditions, Tau co-localisation with acetylated α-tubulin represented 62% of the total Tau 
above threshold. This increased slightly to 66% after 6 hours of CQ exposure, but 
subsequently fell below the control value to 55% after 24 hours (Table 3.1). However, none of 
the observed changes were significant relative to control conditions. Under control conditions, 
acetylated α-tubulin co-localising with Tau represented 84% of the total acetylated α-tubulin 
above threshold. This value increased to 88% after 6 hours of CQ exposure and after 24 hours 
further to 89% (Table 3.1). However, none of the observed changes were significant relative 
to control conditions. In summary and importantly, based on the co-localisation data (Table 
3.1), Tau does not dissociate from acetylated α-tubulin in response to CQ-induced autophagy 
dysfunction.   
  





Table 3.1: Co-localisation coefficients of Tau and acetylated α-tubulin. Data represented as Mean ± SEM. 
 MOC Tau/Total Acetylated α-
tub/Total 
Control 0,87±0,02 0,62±0,08 0,84±0,05 
6 Hour 0,85±0,03 0,66±0,08 0,88±0,05 
24 Hour 0,83±0,03 0,55±0,08 0,89±0,04 
 






Figure 3.21: Co-localisation between Tau and acetylated α-tubulin under control conditions and after CQ treatment. A scatter plot showing thresholded 
pixel distribution. N=3 independent experiments. Pixels seen in white fall above threshold, but do not necessarily indicate co-localisation. Tau (GFP), Acetylated 
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3.9.2 pTau does not co-localise with acetylated α-tubulin under control 
conditions or during CQ-induced autophagy dysfunction 
3.9.2.1 Line profile intensities of pTau and acetylated α-tubulin 
The intensity profile of acetylated α-tubulin remained as discussed previously in 3.9.1.1, where 
regional intensity hotspots can be observed in areas of signal clustering, suggestive of protein 
aggregation (Fig. 3.22E & F). Under control conditions and during periods of CQ exposure, 
pTau signal intensity was consistently higher in the nucleus of the cell relative to the cytosolic 
regions – indicated by the vertical red and blue lines which denote the nucleus (Fig. 3.22B, F 
&J). 
  
3.9.2.2 pTau co-localisation with acetylated α-tubulin does not occur in the cell 
processes or cytosol and is unaffected by CQ-induced autophagy dysfunction 
The MOC revealed that under control conditions, the sum of the total acetylated α-tubulin and 
pTau pixels that fell above threshold, only 51% co-localised. This increased slightly to 66% 
after 6 hours of CQ exposure, but subsequently declined to 55% after 24 hours (Table 3.2). 
Importantly, this area co-localisation did not manifest in the cell processes or cytosol and no 
significant changes were observed relative to control conditions. Under control conditions, 
pTau co-localising with acetylated α-tubulin represented 79% of the total pTau signal falling 
above threshold. This increased to 88% after 6 hours of CQ exposure and fell slightly to 85% 
after 24 hours (Table 3.2). However, no significant changes were observed relative to control 
conditions. Under control conditions, acetylated α-tubulin co-localising with pTau represented 
13% of total acetylated α-tubulin signal falling above threshold. This did not significantly 
change relative to control conditions after 6 or 24 hours of CQ exposure (Table 3.2). To 
summarise, pTau and acetylated α-tubulin co-localisation did not occur in the cell processes 
or cytosol and no significant changes were observed after CQ-induced autophagy dysfunction. 
Importantly, it should be noted that the threshold regions observed, represent a fairly small 
area of the total cell in the control conditions and after 6 hours of CQ exposure (Fig. 3.22C, G 
& K). Importantly, these data suggest that pTau co-localisation with acetylated α-tubulin is 









Table 3.2: Co-localisation coefficients of pTau and acetylated α-tubulin. Data represented as Mean ± SEM. 
 MOC pTau/Total Acetylated α-
tubulin/Total 
Control 0,51±0,04 0,79±0,12 0,13±0,03 
6 Hour 0,60±0,05 0,88±0,04 0,12±0,03 
24 Hour 0,55±0,07 0,85±0,11 0,12±0,04 






Figure 3.22: Co-localisation between pTau and acetylated α-tubulin under control conditions and after CQ treatment. A scatter plot showing 
thresholded pixel distribution. N=3 independent experiments. Pixels seen in white fall above threshold, but do not necessarily indicate co-localisation. 
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3.9.3 Spastin co-localises with acetylated α-tubulin, which significantly and 
progressively increases in response during CQ-induced autophagy 
dysfunction 
3.9.3.1 Line profile intensities of Spastin and acetylated α-tubulin 
Spastin signal intensity remained fairly constant under control conditions and during periods 
of CQ exposure (Fig. 26B, F & J).   
 
3.9.3.2 Spastin co-localisation with acetylated α-tubulin progressively and significantly 
increases during CQ-induced autophagy dysfunction 
The MOC revealed that Spastin and acetylated α-tubulin co-localise under control conditions 
with 68% co-localisation, which progressively and significantly increases to 88% after 24 hours 
of CQ exposure. (Table 3.3). Under control conditions, Spastin co-localising with acetylated 
α-tubulin represented 96% of the total Spastin signal that fell above the threshold. This 
remained constant even after 6 and 24 hours of CQ exposure, respectively (Table 3.3). Under 
control conditions, acetylated α-tubulin co-localising with Spastin represented 86% of the total 
acetylated α-tubulin pixels falling above threshold. This decreased slightly to 71% after 6 hours 
of CQ exposure, but increased significantly to 93% relative to control after 24 hours (Table 
3.3). In summary, Spastin and acetylated α-tubulin co-localise under control conditions and 
progressively co-localise in response to CQ-exposure, to eventual significance after 24 hours 
suggesting an increase in Spastin activity. Of note, these data further suggest that Spastin is 
always associated with acetylated α-tubulin regardless of CQ-exposure (Table 3.3). 
  





Table 3.3 Co-localisation coefficients between Spastin of acetylated α-tubulin. Data represented as Mean 





Control 0,68±0,04 0,96±0,01 0,86±0,03 
6 Hour 0,72±0,04 0,99±0,00 0,71±0,05 
24 Hour 0,81±0,01* 0,99±0,00 0,93±0,02* 
 






Figure 3.23: Co-localisation between Spastin and acetylated α-tubulin under control conditions and after CQ treatment. A scatter plot showing 
thresholded pixel distribution. N=3 independent experiments. Pixels seen in white fall above threshold, but do not necessarily indicate co-localisation. 
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3.9.4 Katanin p60 does not co-localise with acetylated α-tubulin in cell 
processes or cytosol 
3.9.4.1 Line profile intensities of Katanin p60 and acetylated α-tubulin 
The intensity profile of acetylated α-tubulin remained as discussed previously in 3.2.1.1, where 
spikes in the signal intensity can be seen in areas of signal bundling (Fig. 3.24E & F). Katanin 
p60 signal intensity appeared diffusely expressed under control conditions, however after 6 
and 24 hours of CQ exposure, respectively, there appears to be a spike in signal intensity 
within the nuclear regions of the cells (Fig. 3.24F & J). 
 
3.9.4.2 Katanin p60 co-localisation with acetylated α-tubulin does not occur in the cell 
processes or cytosol and is unaffected by CQ-induced autophagy dysfunction  
The MOC revealed that under control conditions 63% of acetylated α-tubulin and Katanin 
signal co-localised of the total signal that fell above the threshold. This decreased to 57% after 
6 hours of CQ exposure and down further to 56% after 24 hours (Table 3.4). Importantly, this 
co-localisation did not occur in cell processes or cytosol and no significant changes were 
observed relative to control. Under control conditions, Katanin co-localising with acetylated α-
tubulin represented 95% of the total Katanin p60 signal falling above threshold. This remained 
fairly constant even after 6 and 24 hours of CQ exposure, respectively (Table 3.4). Under 
control conditions and after 6 of CQ exposure, acetylated α-tubulin co-localising with Katanin 
p60 represented less than 5% of total acetylated α-tubulin signal falling above threshold. This 
increased significantly to 23% after 24 hours of CQ exposure (Table 3.4). To summarise, 
Katanin p60 and acetylated α-tubulin co-localise, but not in cell processes or cytosol and no 
significant changes were observed after CQ-exposure. Moreover, a significant change was 
observed in the amount of co-localisation of acetylated α-tubulin with Katanin p60, but this did 
not occur in cell processes or cytosol (Fig. 3.24C, G & K). These data thus suggest that co-
localisation between Katanin p60 acetylated α-tubulin is unaffected by CQ-induced autophagy 
dysfunction. 
  





Table 3.4: Co-localisation coefficients of Katanin p60 and acetylated α-tubulin. Data represented as Mean 





Control 0,63±0,03 0,95±0,03 0,01±0,01 
6 Hour 0,57±0,03 0,94±0,03 0,03±0,01 
24 Hour 0,56±0,02 0,97±0,01 0,23±0,06
*
 






Figure 3.24: Co-localisation between Katanin p60 and acetylated α-tubulin under control conditions and after CQ treatment. A scatter plot showing 
thresholded pixel distribution. Pixels seen in white fall above threshold, but do not necessarily indicate co-localisation. Acetylated α-tubulin (Alexa Fluor-488), 
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3.10 CQ-induced autophagy dysfunction causes an observable change 
in cellular topology and ultrastructure 
Correlative Light and Electron Microscopy (CLEM) is an extremely powerful technique that 
allows the correlation of fluorescent microscopy with electron microscopy and allows the 
evaluation of protein ultrastructure and cellular topology. In our experimental analysis we 
utilised confocal laser microscopy to assess Alexa 568 against acetylated α-tubulin 
counterstained with Hoechst 33342, and scanning electron microscopy as correlative 
techniques. 
Under control conditions, CLEM analysis revealed that acetylated α-tubulin signal was 
diffusely distributed in the cytosol of cells, however, the signal consistently arranged into an 
intense network like morphology around the perinuclear region of the cell (Fig 3.25A – D). 
After 6 hours of CQ exposure, acetylated α-tubulin became less diffusely distributed in the 
cytosolic compartments and processes, instead arranging into dense filamentous structures 
around clear voids that formed in the cellular structure (Fig 3.25E – H) 
After 24 hours of CQ exposure, the general cellular morphology decreased in size and cells 
visibly stressed. Minimal diffusely distributed acetylated α-tubulin signal was observed in 
cytosolic compartments or in processes. Majority of the signal arranged into dense filamentous 
structures in the cellular processes as well as forming network like patterns around vacuolar 
structures. Furthermore, breaks were observed in the parts of the networks (Fig 3.25I – L) 
In summary, the results suggest that CQ-induced autophagy dysfunction impacts cellular 
morphology by affecting acetylated α-tubulin signal distribution and possibly in response to 
the formation of autophagic vacuoles. 
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Figure 3.25: CLEM analysis of SEM and confocal microscopy assessing acetylated α-tubulin signal distribution in response to CQ-induced autophagy dysfunction. 
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Chapter 4: Discussion 
The microtubulin network is an important part of the cytoskeleton, acting as a track for vesicle 
and organelle transport (Mitchison & Kirschner 1984). It is a very dynamic structure, changing 
its shape according to the cell’s requirements – shrinking and growing, i.e. treadmilling, during 
specific periods such as cell division, process formation and neuronal migration (Desai & 
Mitchison 1997). Tau is an important microtubule associated protein that serves to stabilise 
this network during these dynamic changes, with phosphorylation regulating its binding affinity 
for microtubulin (Avila et al. 2004). In Alzheimer’s disease Tau becomes hyperphosphorylated 
and permanently dissociates from the network, aggregating into insoluble and cytotoxic 
structures termed Neurofibrillary Tangles (Braak & Del Tredici 2014). At the same time, 
microtubules decrease in mass and density and this negatively impacts the ability of the cell 
to maintain functional axonal transport (Braak et al. 1994). There is no mechanistic evidence 
to suggest that Tau dissociation directly causes this loss in microtubulin mass and it is not 
clear when Tau dissociation occurs within the disease pathogenesis (Sudo & Baas 2011; Jean 
& Baas 2013). Subsequent studies have suggested that Tau may in fact protect the 
microtubule from proteins which directly cleave it (Mandelkow et al. 2004). Katanin and 
Spastin are the most characterised severing enzymes that are known to cleave the 
microtubule and further research has proven that their activity is affected by the presence of 
Tau on the microtubule (Qiang et al. 2006; Yu et al. 2008). The pathological mechanisms 
upstream to the onset of Tau hyperphosphorylation still remain largely unknown. Autophagy 
plays a vital role in maintaining the turnover of Tau and numerous studies have suggested 
that inhibition of autophagy leads to an increase in Tau aggregation and phosphorylation (Lee 
et al. 2013; Krüger et al. 2012; Wang et al. 2009; Wang & Mandelkow 2012; Hamano et al. 
2008). However, the underlying mechanisms that govern Tau aggregation and subsequent 
microtubulin instability are neither fully understood nor characterized. In addition, it is not 
known to what extent autophagy dysfunction influences the pathological changes associated 
with microtubule destabilisation, Tau aggregation and proteotoxicity. 
Here we hypothesized that autophagy disruption causes Tau to accumulate intracellularly and 
on the microtubulin network. Accumulated Tau associated with the microtubule becomes 
hyperphosphorylated, reducing its binding affinity and ultimately causing its dissociation. This 
in turn increases microtubule susceptibility to severing enzymes such as Spastin and Katanin, 
causing its fragmentation and dysfunction. It is further hypothesized that these events occur 
prior to the onset of cell death. 
We treated GT1-7 cells with the autophagy inhibitor Chloroquine diphosphate (CQ) to induce 
a state of autophagy disruption. To confirm autophagy dysfunction we utilised Western blot 





analysis to assess LC3 and p62 protein levels in response to the treatment intervention in the 
presence and absence of Bafilomycin A1 (BAF). To determine the effects of CQ-induced 
autophagy dysfunction on microtubulin stability we assessed acetylated α-tubulin protein 
levels – a marker for stable microtubules – utilising Western blot analysis and visualised its 
structure and distribution using confocal, super-resolution structured illumination (SR-SIM) 
and STORM microscopy. To determine the effects of CQ-induced autophagy dysfunction on 
Tau phosphorylation and aggregation we assessed relative protein levels of total Tau and 
pTau utilising Western blot analysis and measured co-localisation between Tau and 
acetylated α-tubulin, as well as pTau and acetylated α-tubulin, utilising SR-SIM and confocal 
microscopy. Finally, to determine the effects of CQ-induced autophagy dysfunction on 
severing enzymes, we performed Western blot analysis to assess Spastin and Katanin p60 
protein levels and visualised and measured the extent of co-localisation with acetylated α-
tubulin. 
Here we will discuss and interpret our results in the context of available literature. Finally we 
will conclude with proposed mechanisms underlying the effect of autophagy dysfunction and 
the pathological changes associated with Tau aggregation and subsequent microtubulin 
destabilisation. 
 
4.1 The effect of CQ treatment on autophagy function 
4.1.1 CQ treatment causes a significant reduction in cell viability 
Functional disruption of autophagy leads to the aberrant accumulation of undigested protein 
and is implicated in the clinical pathogenesis of numerous neurodegenerative diseases 
including Alzheimer’s disease (Hara et al. 2006; Loos et al. 2013; Nixon 2013) 
Chloroquine (CQ) is an autophagy inhibitor that exerts its effects by accumulating in 
lysosomes and raising the luminal pH, inhibiting the vacuolar type H+-ATPase pump and thus 
preventing functional acidification (Llewellyn et al. 2015). From our results we determined that 
100 μM CQ was sufficient to induce a significant reduction in viability of GT1-7 cells after 24 
hours of treatment, but mild enough to induce a modest non-significant reduction after 6 hours 
(Fig 3.1). This finding was in agreement with our experimental aims which allowed us to 
assess any changes in the defined parameters prior to and during the onset of cell death. 
Furthermore, these time points also served translationally as a model system that mirrors the 
clinical representation of a pre-symptomatic undiagnosed AD patient and a diagnosed AD 
patient – at which time a significant amount of neuronal death has occurred and symptoms 
have manifested. 





The concentration of CQ used is in agreement with a study that investigated the effects of CQ 
on ubiquinated protein and p62 degradation (Myeku & Figueiredo-Pereira 2011). However, a 
recent review has highlighted that treating cells with more than 50 μM of CQ for 4 hours can 
induce p53-mediated caspase-independent cell death in mouse tissue (Sharifi et al. 2015; 
Maclean et al. 2008). Although, another study suggests that CQ-mediated cell death occurs 
in both a caspase- and p53-independent manner, instead of inducing cell death through the 
accumulation of autophagic vacuoles. Here, however, human glioblastoma cell line models 
were used and the exact molecular mechanisms underlying the cell death onset remained to 
be elucidated (Geng et al. 2010). This basis of these studies indicate the probable mode of 
cell death occurring after 24 hours of CQ exposure and highlights the severity of the insult. 
 
4.1.2 CQ treatment leads to a progressive accumulation of LC3-II protein 
CQ treatment led to a progressive accumulation of LC3-II over time (Fig 3.2 & 3.3), confirming 
autophagosome accumulation and therefore autophagy dysfunction. CQ has consistently 
been shown to inhibit autophagy in both in vitro and in vivo studies (Murakami et al. 1995; 
Murakami et al. 1998; Bendiske & Bahr 2003; Shacka et al. 2006; Hamano et al. 2008; Yoon 
et al. 2010). Assessing LC3-II protein levels in response to treatment, in the presence or 
absence of Bafilomycin A1 (BAF), was used to indicate the effect of CQ on the relative 
autophagic flux – the rate of autophagosome synthesis vs autophagosome degradation – of 
the system. BAF is most often referenced in literature as only inhibiting autophagy through the 
prevention of fusion between autophagosomes and lysosomes, but in fact it additionally also 
prevents lysosome acidification through inhibition of the vacuolar type H+-ATPase pump 
(Klionsky et al. 2008). It is reasoned that the specific mode of action is determinant on the time 
of exposure (Klionsky et al. 2008). The relative autophagic flux of GT1-7 cells under basal 
conditions appeared to be very low, as evidenced by the minor increase in LC3-II protein levels 
in cells treated with BAF (400 nM) when compared to the untreated control cells LC3-II protein 
levels (Fig 3.2). This is not unusual for neurons, as measuring autophagic flux in this tissue 
type has historically been recognised as challenging due to the unexpected responses of 
generally used autophagy modulators and the contentious scrutiny of published results 
(Mizushima 2003; Rubinsztein & Nixon 2010). It is generally thought that the flux in neurons 
is high due their high metabolic needs (Nixon & Yang 2011). 
Several reasons may explain these results. Initially, it was thought that the concentration of 
BAF used was not sufficient, however, it is significantly higher than the concentrations used 
in the literature, which ranges from 1 nM – 200 nM (Pivtoraiko et al. 2010; Shacka et al. 2006; 
Li et al. 2012). The amount of time that the cells were exposed to BAF (120 min) may have 





been insufficient, however, prior work by others has shown that BAF elicits effects at lower 
doses for even shorter exposure times (Shacka et al. 2006; Klionsky et al. 2008). Furthermore, 
we exposed the cells to BAF after the CQ treatment concluded, which may have allowed the 
cells to recover. However, this is an unlikely factor due to the increase in the LC3-II protein 
levels in cells treated with both CQ and BAF at 6 hours compared to cells treated with CQ 
alone (Fig 3.2). BAF has been shown to be a more potent autophagy inhibitor than CQ, even 
at lower concentrations compared to that utilised in the present study (Ni et al. 2011; Sahani 
et al. 2014). In addition, BAF has also been shown to attenuate CQ-induced cell death, but 
does not attenuate CQ-induced autophagy inhibition (Shacka et al. 2006). Lastly, it has been 
shown that BAF may also inhibit the proteasome and endosome trafficking, amongst other 
processes (Klionsky et al. 2008) 
A major drawback of assessing autophagic flux using Western blotting is that it is less suitable 
to actually measure flux, which is defined as the rate of autophagy mediated degradation over 
time (Rubinsztein et al. 2009; Klionsky et al. 2012). There is no parameter of time moving 
forward when considering the flux of the system in this manner, merely a change in the system 
at one point in time relative to another. Therefore Western blot results of LC3-II should be 
interpreted with caution and should always reported as relative change, since a continuous 
measurement is not taken (Loos et al. 2014). 
According to the results observed in cells following 6 hours of CQ treatment compared to the 
cells following 6 hours of CQ treatment and BAF, there is an increase in LC3-II accumulation 
(Fig 3.2). Although this is not a significant difference, it may suggest that CQ not only inhibits 
autophagosome degradation, but also enhances autophagosome formation (Rubinsztein et 
al. 2009). Furthermore, because of the modest additive effect of CQ in the presence of BAF 
on LC3-II accumulation, it supports the notion that not only is the relative rate of total 
autophagic turn-over in GT1-7 cells low at basal conditions, but also that CQ most likely 
induces maximal inhibition of autophagy after 6 hours of exposure. 
After 24 hours of CQ exposure, we observed a significant increase in LC3-II protein levels 
relative to control, suggesting major autophagosome accumulation. At this time a significant 
reduction in cell viability was observed after 24 hours of CQ exposure and given that both CQ 
and BAF are extremely cytotoxic it is possible that the cumulative toxicity had an effect on 
LC3-II protein levels. In summary, these findings demonstrate the ability of the intervention 
employed to impact autophagy function by inhibiting autophagosome degradation, therefore 
establishing a powerful model system. 





4.1.3 CQ treatment leads to a progressive decrease in p62 protein 
CQ-induced autophagy dysfunction led to a progressive decrease in p62 protein levels over 
time (Fig 3.4). The decrease was enhanced when cells were treated with BAF after both 6 
hours and 24 hours of CQ exposure, respectively. This suggests that p62 is either being 
degraded even when autophagy was being functionally disrupted, or its synthesis ceased. 
There are multiple reasons to explain these results. Briefly, the sequestosome1/p62 targets 
poly-ubiquinated proteins to the forming autophagosome for selective degradation by acting 
as an adaptor protein between LC3-II residues and the tagged protein (Barth et al. 2010). It is 
therefore used as a marker for selective autophagy activity, but it is also viewed as an 
autophagy target itself (Barth et al. 2010). Furthermore, p62 also has a role in the proteasome 
pathway (UPS) and its expression is also regulated at a transcriptional level by oxidative stress 
and other signalling pathways, such as Ras or NFκ-B, that are independent of autophagy 
(Moscat & Diaz-meco 2009; Myeku & Figueiredo-Pereira 2011). Therefore taking the literature 
in account, interpretation of our p62 results should be approached with caution. 
The fact that p62 protein levels continued to decline in the presence of both CQ and BAF may 
have multiple reasons (Fig 3.4). Firstly, since p62 is also a UPS target, it may be as a result 
of a compensatory increase in UPS activity in response to CQ-mediated autophagy inhibition. 
Indeed, it has been shown that inhibition of autophagy can lead to compensatory responses 
by the UPS (Ding et al. 2007). Secondly, it may not necessarily be an increase in p62 
degradation that we observed, but a decline in p62 transcription. This explanation seems 
plausible since it is known that p62 transcription is affected by autophagy-independent 
signalling (Barth et al. 2010). However, Sahani and colleagues have shown that p62 mRNA 
levels remained unchanged in Mouse Embryonic Fibroblasts (MEFs) in response to CQ 
treatment, even though they also observed a time dependent decrease in p62 protein levels 
(Sahani et al. 2014). Lastly, the results may suggest that CQ does not completely inhibit 
autophagy. Indeed, others have shown that CQ does not completely inhibit p62 degradation 
even in the presence of LC3-II accumulation (Sahani et al. 2014; Gomez-Sanchez et al. 2016). 
However, this scenario remains unlikely simply because the cells additionally treated with BAF 
displayed a similar decrease in p62 protein levels (Fig 3.4). Of note, it may also be a decrease 
in protein poly-ubiquitination that caused p62 protein levels to decline, although this too 
remains unlikely as it has been shown that CQ treatment in fact increases protein poly-
ubiquitination (Myeku & Figueiredo-Pereira 2011). 
In summary, although the results in p62 protein levels in response to CQ treatment may 
suggest incomplete inhibition of autophagy-mediated p62 degradation, it is clear that the 
mechanisms governing p62 protein levels and activity are highly complex. Furthermore, our 





LC3-II Western blot results are in strong agreement with literature that autophagy was indeed 
successfully and progressively inhibited. Finally, we also suspect that the increased induction 
of autophagosome synthesis may be a compensatory response by the cell due to the stress 
brought about by the abundance of undigested autophagosomes. 
 
4.2 The effect of progressive CQ-induced autophagy dysfunction on 
microtubulin stability and structure 
 4.2.1 CQ-induced autophagy dysfunction impacts microtubulin stability over 
time 
Acetylated tubulin is considered as an indicative marker of stable microtubules (Butler et al. 
2007). CQ treatment led to a progressive, but non-significant increase in acetylated α-tubulin 
protein levels over time (Fig 3.5). These results indicate that tubulin stability may be impacted 
by CQ-induced autophagy dysfunction. A limited number of studies performed by others on 
CQ-mediated changes in acetylated α-tubulin protein levels, observed that acetylated α-
tubulin protein levels progressively declined in rat brain slices treated with CQ (Bendiske et al. 
2002; Bendiske & Bahr 2003; Butler et al. 2007). Acetylated α-tubulin is required for the fusion 
of lysosomes and autophagosomes and serves as the preferential recruitment and binding 
site for motor proteins (Bulinski 2007; Dompierre et al. 2007; Xie et al. 2010). CQ deacidifies 
lysosomes, but does not prevent fusion, so it is plausible to suggest that the increase in 
acetylated α-tubulin may be due to the accumulation of autophagosomes and subsequent 
fusion with lysosomes. Indeed, a study conducted on proteotoxicity in cardiomyocytes 
observed that cells synergistically increase acetylation of α-tubulin when autophagy is induced 
in response to protein aggregation (Mclendon et al. 2014). Tubulin acetylation is also required 
for starvation-induced autophagy by modulating the assembly of autophagic cargo along the 
microtubule during nutrient deprivation (Geeraert et al. 2010). 
In summary, acetylated α-tubulin protein levels increased suggesting that CQ-induced 
autophagy dysfunction causes tubulin to stabilise, which is likely a compensatory response of 
the cell to stress. 
 
4.2.2 CQ-induced autophagy dysfunction disrupts microtubulin structural 
organisation 
Changes were observed in acetylated α-tubulin signal distribution from a diffuse cytoplasmic 
and well-organised perinuclear structure under control conditions to a densely structured, 





aggregated network over the course of CQ exposure in confocal (Fig 3.6), SR-SIM (Fig 3.7), 
dSTORM (Fig 3.8) and CLEM (Fig 3.25) derived image data. The increase in condensed 
structured signal and the non-significant increase in acetylated α-tubulin protein levels over 
time suggest that it is newly polymerised tubulin, instead of the modification of existing tubulin 
networks (Fig 3.6 - 3.8 & 3.25). CLEM analysis (Fig 3.25G & H) revealed that some of the 
vacuole-like structures observed during fluorescent microscopy analysis of cells (Fig 
3.11G&K, 3.14K), were in indeed vacuolar structures that formed within the cytoplasm, 
suggesting major impact of the CQ treatment on lysosomal morphology. CLEM also made 
clear that the tubulin network re-arranged, surrounding these sometimes large, vacuolar 
structures. This clearly demonstrates the impact that CQ-induced autophagy has on 
microtubulin cytoskeletal dynamics. In addition, we consistently observed a reduction in cell 
size over time in response to CQ exposure, which appears contradictory to the notion of newly 
polymerised stable tubulin networks. Of note, a similar study found that proteasome inhibition 
led to an increase in acetylated α-tubulin protein levels as well as polymerisation in multiple 
cell lines, which included neurons (Poruchynsky et al. 2008). Although the acetylated α-tubulin 
signal became more structurally condensed over time, changes in the structural morphology 
of the network were observed, resulting in aggregate like formations after 24 hours of CQ 
exposure. Additionally, these changes also manifested and displayed as breakages in 
acetylated α-tubulin structure and clustering of individual fibrillar structures, specifically within 
cellular processes (Fig 3.11J; 3.14G&H; 3.18H). These changes may have impacted overall 
morphology leading to the observed reduction in cell size. 
Our results have relevance in terms of clinical translation as they are supported by a study 
that found a significant increase in acetylated α-tubulin relative to total α-tubulin ratios in AD 
brain tissue compared to age-matched controls – although it should be noted that the overall 
α-tubulin protein levels were also found to be significantly reduced (Zhang et al. 2015). In 
agreement with these authors, we suspect that the increased acetylated α microtubulin protein 
levels may be an adaptive response to compensate for a loss in microtubule mass, but 
additionally we suggest that autophagy dysfunction may contribute to the increased levels of 
acetylated α-tubulin. 
Of note, acetylation of α-tubulin has been shown to improve axonal transport and this has 
furthermore been exploited in AD treatment development with the anti-neoplastic drug 
Paclitaxel (Shemesh & Spira 2011). Paclitaxel is used in the treatment of a multitude of 
cancers, where it induces microtubule stabilisation by enhancing acetylation of tubulin and in 
doing so reduces the proliferative ability of neoplastic cells (Marcus et al. 2005; Shemesh & 
Spira 2011). The drug has been shown to stabilise microtubules in in vivo and in vitro models 
of tauopathy and at low doses, mitigates the cytotoxic effects of Tau pathology on vesicular 





transport (Zhang et al. 2005; Shemesh & Spira 2011). However, the ability of the drug to cross 
the blood-brain barrier (BBB) is low and therefore its development as a treatment for 
neurodegenerative diseases has declined in recent years, but several derivatives and 
paclitaxel hybrid molecules have been investigated as alternatives (Ballatore et al. 2007). 
Recently, Epothilone D (EpoD) a drug that elicits the same microtubulin stabilising effect of 
paclitaxel, but which can cross the BBB, has been show to improve axonal transport and 
cognitive impairment in a mouse model for tauopathy (Zhang et al. 2012). It has further been 
investigated in a clinical trial for therapeutic use in AD, however, the trial ended in 2013 and 
use of EpoD as an AD therapy was subsequently discontinued (See Trial#: NCT01492374). It 
is of interest in this context, that the overall acetylation status may control autophagy. 
However, whether the indicated drugs indeed indirectly impact autophagy remains unclear. 
In summary, our results suggest that the increase in acetylated α-tubulin protein levels and 
aggregation caused by CQ-induced autophagy dysfunction may be a response by the cell to 
compensate for the loss in microtubule mass in order to preserve structural functionality of the 
microtubulin network and to improve the axonal transport, which may have been impaired due 
to the accumulation of autophagosomes. 
 
4.3 The effect of progressive CQ-induced autophagy dysfunction on 
Tau and pTau protein levels, localisation and co-localisation with 
stable microtubulin 
4.3.1 CQ-induced autophagy dysfunction leads to a non-significant decrease 
in Tau protein levels  
Endogenous total Tau protein levels progressively, but non-significantly declined, in response 
to CQ-induced autophagy dysfunction (Fig 3.9 & 3.10). This suggests that total Tau is not only 
being degraded, but the enhanced degradation may take place as a response to autophagy 
dysfunction brought about by CQ exposure. Our results are contradictory to the available 
literature, where it has been consistently found that Tau protein levels progressively increase 
in response to CQ treatment in in vitro, in vivo and ex vivo studies (Murakami et al. 1998; 
Oyama et al. 1998; Takeuchi 2001; Bendiske et al. 2002; Bendiske & Bahr 2003; Hamano et 
al. 2008; Wang et al. 2009; Torres et al. 2012). However, autophagy is not the only proteolytic 
pathway within mammalian systems and therefore our results of reduced total Tau protein 
levels in the wake of CQ-induced autophagy dysfunction may point towards alternative 
degradation pathways (Lee et al. 2013). Indeed, Tau has many isoforms, as well as truncated 
variants, which are found to be degraded through both the UPS and the ALP, as well as other 





systems (Lee et al. 2013). Generation of truncated forms of Tau at Asp421 have been 
identified to be critical to the formation of NFTs, in fact, this appears to occur very early in the 
NFT evolution (Guillozet-Bongaarts et al. 2005). Truncation of Tau at Asp421 increases its 
fibrillogenic properties and its protein levels are abnormally high in the AD brain (Dolan & 
Johnson 2010). Furthermore, others have found that truncated Asp421 Tau is preferentially 
degraded through the ALP, whereas full length Tau was preferentially degraded through the 
UPS (Dolan & Johnson 2010). However, degradation of full length Tau has recently received 
major attention, with numerous studies providing evidence for both ALP and UPS driven 
degradation (Lee et al. 2013). In light of our findings it is clear that autophagy functionality 
affects the dynamics of Tau degradation, whether this is a direct or indirect effect remains to 
be fully elucidated. 
In order to quantify total Tau protein levels we utilised the CP27 antibody for Western blot 
analysis which provides an advantage by detecting a sequence in human Tau that is 
conserved across all isoforms and which shares ~88% sequence homology with murine Tau 
variants, ranging from amino acid sequence 130 to 150 (Petry et al. 2014). However, a 
disadvantage is that CP27 cannot detect all truncated forms of Tau because not all the 
truncated variants express the target sequence, especially Tau (Asp421). Of note, an 
important observation was that both p62 and total Tau protein levels decreased in response 
to CQ exposure (Fig 3.4 & 3.9), which further adds to the speculation of compensatory 
induction of UPS activity. Indeed, Babu and colleagues have shown that Tau degradation 
through the UPS is dependent on p62 recognition of K63 specific poly-ubiquitination chains. 
Furthermore, others have also shown that inhibiting autophagy in rat brain slices resulted in 
an upregulation of calpain-dependent proteolysis of Tau (Zhang et al. 2009). 
In summary, although a decrease in Tau protein levels was witnessed during CQ-induced 
autophagy dysfunction, it was not a trend leading towards significance. Nonetheless, it is clear 
that a degree of total Tau degradation was taking place. Interpreting these results in context 
of the decrease in p62 protein levels may indicate a compensatory upregulation of UPS 
dependent proteolysis of Total Tau. Further work is thus required to assess the effect of CQ-
induced autophagy dysfunction on poly-ubiquitination of Tau as well as targeting of Tau by 
p62, which can be performed with the aid of co-immunoprecipitation studies. Assessing Tau 
and p62 mRNA levels utilising qPCR techniques may also elucidate potential effect of CQ-
induced autophagy dysfunction on gene transcription. 





4.3.2 CQ-induced autophagy dysfunction causes progressive aggregation of 
Tau, without inducing dissociation from stable microtubulin 
In order to assess Tau localisation we utilised SR-SIM microscopy to visualise Tau, using a 
transfected GFP-Tau construct. In spite of the reduced protein levels of endogenous Tau, we 
demonstrated that transfected GFP-Tau progressively aggregated over time during CQ 
exposure (Fig. 3.11H & L). Furthermore, after 6 hours of CQ-exposure the aggregates formed 
within vacuolar-like structures resembling autophagosomes (Fig 3.11H). This result is 
consistent with findings by Murakami and others in the brain slices of a CQ-treated rat model 
(Murakami et al. 1998). 
Importantly, despite the reduction in endogenous Tau protein levels and progressive 
aggregation of GFP-Tau in response to CQ-induced autophagy dysfunction, no significant 
differences in co-localisation was observed between stable microtubulin and GFP-Tau over 
time, suggesting no dissociation of Tau took place (Table 3.1). However, although GFP-Tau 
did not dissociate from acetylated α-tubulin, it did progressively aggregate in response to the 
CQ-induced autophagy dysfunction, suggesting upregulation of GFP-Tau synthesis rather 
than an aggregation of dissociated GFP-Tau. Furthermore, GFP-Tau accumulated 
preferentially in the cell periphery and processes over time (Fig. 3.11). Similarly, Zempel and 
Mandelkow found that exposure of primary neurons to oligomeric Aβ mediated the missorting 
of newly synthesized Tau into somatodendritic compartments (Zempel & Mandelkow 2014), 
supporting our findings. Of note Tau mRNA has been shown to non-randomly localise as 
discrete granules of RNA along neuronal axons (Aronov et al. 2002), which may suggest a 
mechanism of newly synthesized Tau, as discussed above. Tau synthesis has been shown to 
be enhanced through Insulin-dependent activation of the mTOR/PI3K pathway (Nemoto et al. 
2011). Additionally, the study confirmed that it was indeed enhanced protein synthesis rather 
than an increase in gene transcription through the use of cyclcohexamide, a protein synthesis 
inhibitor, and actinomycin D, an inhibitor of gene transcription (Nemoto et al. 2011). However, 
the molecular mechanisms underlying the regulation of Tau synthesis still remain largely 
unknown, although it has been demonstrated that some cellular factors such as fibroblast 
growth factor (FGF) enhance its synthesis, these aspects deserve further study (Medina & 
Avila 2014). 
Of note, in a model for Tau pathology in AD, some have documented what they suggest to be 
critical steps in Tau-mediated neurodegeneration (Baas & Qiang 2005). It is suggested that 
excess Tau initially binds to microtubules and prevents microtubule-Kinesin binding, which 
hinders axonal transport (Baas & Qiang 2005). Tau is then hyperphosphorylated which 
decreases its affinity causing dissociation, which in turn triggers recruitment of severing 





enzymes to the microtubules and subsequently leads to fragmentation and destabilisation of 
the network (Qiang et al. 2006). In our results Tau co-localised with acetylated α-tubulin and 
remained co-localised during autophagy dysfunction, suggesting no dissociation of Tau from 
microtubulin (Table 3.1) (Fig 3.21). We further observed breakages in the microtubulin 
structure during late CQ-induced autophagy dysfunction despite no changes in Tau co-
localisation with acetylated α-tubulin (Fig 3.11J; 3.14G&H; 3.18H), which suggests that the 
destabilisation of acetylated α-tubulin structure was occurring independent of Tau association. 
In summary, our results show that CQ-induced autophagy dysfunction causes Tau to 
aggregate in cell processes, but at the same time preserves and maintains co-localisation with 
acetylated α-tubulin networks. Furthermore, the association of Tau with acetylated α-tubulin 
networks did not prevent their destabilisation that may have been induced by autophagy 
dysfunction. 
 
4.3.3 CQ-induced autophagy dysfunction causes an increase in Tau 
phosphorylation as an early event, but does not maintain the 
phosphorylation status 
In order to quantify pTau protein levels we utilised Western blot analysis with an antibody that 
recognises phosphorylation of Tau on the Ser400/403/Ser404 amino acid residues. CQ-
induced autophagy dysfunction caused a non-significant increase in Tau phosphorylation after 
6 hours, relative to the control, but this was not maintained and subsequently declined to levels 
lower than those of control conditions after 24 hours (Fig 3.12). In a separate time course 
using Western blot analysis, pTau protein levels were also quantified in response CQ every 
two hours for 24 hours (Fig 3.13). These results contrastingly suggested that the pTau 
significantly increase relative to the 0H control after 6 and 24 hours. However, it should be 
noted that the sample size for this experiment was small and the standard error of the mean 
was large – reducing the statistical power. Nonetheless the trend observed after 6 hours of 
CQ exposure is similar to the 6 hour group in 3.5.1, which had a larger sample size (Fig 3.12). 
Furthermore, the trend seen after 16 hours is non-significantly decreasing which shows 
similarity with our previous findings (Fig 3.12). 
Others have shown that CQ-induced autophagy perturbations caused Tau to accumulate and 
aggregate, but found no significant differences in phosphorylation (Hamano et al. 2008). What 
remains unknown is whether the increase in phosphorylation we observed was directly due to 
CQ-induced autophagy dysfunction or an indirect activation of enzymes known to 
phosphorylate Tau such as AMPK. 





A plausible explanation for enhanced AMPK activity lies in the effect of CQ has on enhanced 
autophagy induction. AMPK, a metabolic sensor, is central to autophagy induction during 
starvation and periods of stress. It is activated through phosphorylation and induces 
autophagy through the mTOR-dependent pathway (Singh & Cuervo 2011). AMPK has been 
found to be abnormally activated in NFT-bearing neurons in AD and has furthermore been 
directly shown to phosphorylate Tau and mediate Tau pathology in vivo (Vingtdeux et al. 2011; 
Domise et al. 2016).  
 
4.3.4 CQ-induced autophagy dysfunction does not impact pTau aggregation, 
localisation or changes in co-localisation with stable microtubulin 
We observed no aggregation of pTau after 6 hours of CQ-induced autophagy dysfunction 
despite an increase in protein levels, albeit non-significant (Fig 3.12). To our surprise, we 
consistently observed that pTau primarily localised in the nucleus under control conditions, 
which was preserved after 6 and 24 hours of CQ exposure, respectively (Fig 3.12). 
Furthermore, no significant differences were observed in co-localisation between pTau and 
stable acetylated α-tubulin (Table 3.1), suggesting that pTau does not dissociate from 
microtubulin upon autophagy failure. The area of co-localisation appeared to increase and 
more a more structured pattern formed over time (Fig. 3.22C, G &K). However, one needs to 
consider that the cell size progressively decreased over time causing condensation of all 
fluorescent signals, which may impact the area of co-localisation. Furthermore, no co-
localisation was observed in cytosolic areas rich in acetylated α-tubulin signal (Fig 3.22). 
Given that Tau is a microtubule associated protein and that phosphorylation modulates its 
binding affinity, we expected that pTau would not co-localise with tubulin per se, but would 
localise within close proximity. The fact that pTau localised in an organised dot-like fashion 
within the nucleus around euchromatin (Fig 3.14D, H & L), suggests that it may have 
transcription factor-like properties. Indeed, Tau has previously been detected in the nucleus, 
where it is suggested to have a protective effect on DNA in response to heat shock stress and 
to be putatively involved in normal nucleolar organisation (Sjöberg et al. 2006; Sultan et al. 
2011). Furthermore, a comprehensive study on the protein profiles of different Tau isoforms 
in the murine brain revealed that the 1R/2N Tau variant was predominantly expressed in cell 
nuclei (Liu & Gotz 2013). Since GT1-7 cells are murine derived, these data support our 
observation. It also provides a possibility for our observation of pTau localisation (Fig 3.14D, 
H & L), suggesting that this isoform is preferentially phosphorylated even under control 
conditions. 





Furthermore, we speculate that the reason for its localisation in the nuclear region is due to 
the dynamic properties of nucleus, which includes constant remodelling due processes such 
cell division and protein synthesis. These processes are mostly dependent on the microtubulin 
network, especially chromatin separation, which may require the network to undergo similar 
remodelling events (van der Vaart et al. 2009). Thus it may explain the observed constant 
protein levels of pTau in this region. Taken together, the provided evidence supports the notion 
of constant nuclear pTau localisation. 
Finally, Tau possesses multiple serine and threonine sites capable of being phosphorylated 
and the antibody we utilised only recognised 3 of these sites, Ser400, Thr403 and Ser404. 
Phosphorylation of Tau at Ser404 is associated with an inhibited ability to promote microtubule 
assembly, which is supportive of our experimental findings (Evans et al. 2000). Future studies 
may hence additionally assess other sites of phosphorylation in response to CQ-induced 
autophagy dysfunction. 
In summary, Tau phosphorylation increased after 6 hours of CQ exposure, which may be due 
to an increase in AMPK activity caused by CQ-induced autophagosome synthesis. However, 
the phosphorylation was not maintained after 24 hours of CQ exposure. Furthermore, pTau 
did not form aggregates in the cell, but instead localised within the nucleus under control 
conditions and after CQ-exposure, which we suggest may be a protective effect, potentially 
impacting DNA in response to stress. Further work is thus required to elucidate the role of 
pTau during autophagy dysfunction, which may include Western blot analysis of cell lysate 
nuclear fractions or chromatin immunoprecipitation (ChIP).  
 
4.4 The effect of progressive CQ-induced autophagy dysfunction on 
Spastin protein levels, localisation and co-localisation with stable 
microtubulin 
4.4.1 CQ-induced autophagy dysfunction causes progressive, but non-
significant accumulation of Spastin 
Spastin is a hexameric protein that possesses the capability of cleaving the microtubule 
through the hydrolysis of ATP. Mutations in the SPG4 gene which encodes for Spastin, are 
the cause of 40% of Autosomal dominant – Hereditary Spastic Paraplegia (AD-HSP) cases 
(Charvin et al. 2003). In a murine model for the disease it was shown that mutated Spastin 
caused gross focal swellings in cortical neuron axons resulting in transport deficits (Tarrade 
et al. 2006). 





In our model of CQ-induced autophagy dysfunction, Spastin protein levels progressively 
increased over time, however, it was not a trend leading to significance. There is no contextual 
literature to indicate how the turnover of Spastin is mediated. However, taking into account 
that the increase in protein levels was not significant, it is likely an indirect effect of autophagy 
dysfunction rather than an indication that autophagy plays a role in Spastin turnover itself. 
 
4.4.2 CQ-induced autophagy dysfunction causes no changes in Spastin 
localisation, but leads to a progressive and significant increase in co-
localisation with stable microtubulin 
Under control conditions, Spastin diffusely localised in the cytosol and cell processes, but also 
formed punctate structures arranging in proximity to euchromatin in the nucleus (Fig 3.23). 
The signal in the cytosol remained unchanged after 6 and 24 hours of CQ-induced autophagy 
dysfunction, respectively. However, the punctate structures in the nucleus progressively 
decreased in intensity and frequency after CQ-induced autophagy dysfunction. Spastin has 
mainly two isoforms, M1 and M87. M87 is mainly cytosolically localised, whilst M1 favours ER 
and nuclear localisation. In our experiments the antibody used to assess Spastin localisation 
detected the total protein, however, we suspect that the punctate structures observed in the 
nucleus may indeed be the M1 isoform based on findings by others (Charvin et al. 2003; 
Claudiani et al. 2005; Solowska et al. 2008). Further work is required to confirm if the punctate 
structures are indeed the M1 isoform, which may include Western blot analysis using cellular 
nuclear fractions. 
Under control conditions, there is moderate co-localisation between Spastin and stable 
microtubulin in the cytosol and processes of the cell. After CQ-induced autophagy dysfunction 
the co-localisation progressively increased to significance after 24 hours (Table 3.3). 
Interestingly, Spastin always appeared to co-localise with stable tubulin regardless of whether 
the cells were exposed to CQ or not (Table 3.3). However, observing the significant increase 
in stable microtubulin co-localising Spastin relative to control (Table 3.3) and taking into 
account the overall increase in acetylated α-tubulin protein levels, it indicates that the increase 
in co-localisation between Spastin and stable microtubulin is due to an increased acetylated 
α-tubulin protein levels. 
This result allows us to deduce two aspects. Firstly, Spastin can interact with the microtubule 
whether Tau is bound to the network or not, unlike Katanin p60. Indeed, this finding is 
consistent with the literature which shows that Spastin activity is not inhibited by the presence 
of Tau on the microtubule (Sudo & Baas 2010). Secondly, it would appear that Spastin is 
recruited by acetylated α-tubulin which is in contrast to previous studies, showing Spastin 





preferentially binds to and severs polyglutamylated microtubulin when compared to acetylated 
microtubulin (Lacroix et al. 2010; Zempel et al. 2013; Zempel & Mandelkow 2015). However, 
in these studies the polyglutamylation was induced through Aβ exposure and we did not 
investigate microtubulin polyglutamylation in this nor any other post-translational modification 
in context of CQ-induced autophagy dysfunction. Furthermore, one of these studies also 
showed that the Aβ exposure caused Tau missorting which subsequently led to the 
mislocalisation of the enzyme TTLL6 (Tubulin-Tyrosine-Ligase-Like 6) into neuronal dendrites. 
TTLL6 pathologically caused polyglutamylation of microtubulin, which induced Spastin 
recruitment and cleavage of the network (Zempel & Mandelkow 2015). In summary, although 
we did not directly measure Spastin activity in response to CQ-induced autophagy dysfunction, 
the increase in co-localisation between Spastin and acetylated α tubulin does infer an increase 
in its activity. Furthermore, the changes in acetylated α-tubulin ultrastructure observed after 
24 hours of CQ exposure (Fig 3.6 - 3.8 & 3.25), in which breaks in fibrillar structures were 
apparent and the overall cell morphology became smaller, support the notion that Spastin 
activity was indeed increased.  
 
4.5 The effect of progressive CQ-induced autophagy dysfunction on 
Katanin p60 protein levels, localisation and co-localisation with 
stable microtubulin 
4.5.1 CQ-induced autophagy dysfunction causes a significant and progressive 
accumulation of Katanin p60 over time 
Utilising Western blot analysis we quantified Katanin p60 protein levels in response to CQ-
induced autophagy dysfunction. Katanin p60 protein levels progressively increased relative to 
control conditions in response to CQ-induced autophagy dysfunction, significantly so after 24 
hours of CQ exposure (Fig 3.17). This suggests that either autophagy plays a role in the turn-
over of Katanin p60 or its protein levels are indirectly affected by CQ-induced autophagy 
dysfunction. To the best of our knowledge there is no available literature to support our 
findings. However, recent research provides evidence that suggests that Katanin p60 turn-
over is in fact mediated by proteasome degradation through targeting by the C terminus of 
Hsp70-interacting protein (CHIP) (Yang et al. 2013). These findings may point towards the 
possibility of Katanin targeted to the autophagy machinery. Whether indeed Katanin is cargo 
for macroautophagy could be confirmed with Bafilomycin A1 treatment since it prevents 
autophagosome and lysosome fusion – Katanin p60 protein levels should increase. 
Furthermore, the effect of CQ-induced autophagy dysfunction of Katanin p60 synthesis and 
gene transcription should be assessed through the use of cyclcohexamide and actinomycin D 





to further confirm that Katanin p60 is indeed an autophagy target and the results observed are 
not due to enhanced protein synthesis or gene transcription. 
The Katanin p60 protein levels in neurons are high, so that stoichiometrically it should be able 
to cleave all the microtubules in cell at any given time, which has put to question how its activity 
is regulated (McNally et al. 2002). In xenopus egg extracts it was found that Katanin p60’s 
activity could be modulated by XMAP230 – a MAP4 homolog – and cyclinB/cdk1, which tied 
its regulation to the cell cycle (Vale 1991; McNally et al. 2002). Furthermore, they found that 
Katanin p60 activity was also higher in cells undergoing mitosis when compared to cells in 
interphase and this was related to the cells phosphorylation status (McNally et al. 2002). 
However, Katanin has so far not been found capable of being phosphorylated and this has led 
others to investigate other microtubule associated proteins (Baas & Qiang 2005). In a 
provocative study, Qiang and colleagues investigated Tau as a possible mediator of Katanin 
p60 activity in neurons due to the importance of phosphorylation in regulating its binding 
capacity. Furthermore, this speculation was additionally based on the findings of their previous 
experiments where Katanin p60 was over-expressed in cultured neurons and it was observed 
that microtubules in axons and dendrites, which are richer in Tau relative to somatic 
compartments, were more resistant to cleavage (Qiang et al. 2006). 
These data suggest to consider the effect of a significant increase in Katanin p60 protein levels 
may have on the microtubulin network and cellular structure. 
 
4.5.2 CQ-induced autophagy dysfunction causes no changes in Katanin p60 
localisation or significant differences in co-localisation with stable 
microtubulin 
Visualisation of Katanin p60 revealed minor localisation within the cytoplasm, with a 
predominant localisation in the nucleus. After 6 and 24 hours of CQ-induced autophagy 
dysfunction, Katanin p60 appeared preferentially localised in the nucleus of the cells (Fig 
3.18). This is indeed a surprising finding, since even under control conditions one would expect 
to observe higher protein levels in the cytosol and processes according to the literature (Yang 
et al. 2013). Furthermore, no co-localisation between Katanin and stable tubulin was observed 
in the cytosol under control conditions or after CQ exposure for 6 or 24 hours, respectively 
(Fig 3.25). However, more acetylated α-tubulin co-localised with Katanin p60 after 24 hours of 
CQ exposure relative to control, remaining low nonetheless at 23% co-localisation and 
represented a small and localised area of the cell (Table 3.4) (Fig 3.24). The significance was 
likely due to the progressive increase in both Katanin p60 and acetylated α-tubulin protein 
levels.  





Although we observed no co-localisation between Katanin p60 and stable tubulin in the cytosol 
under control conditions or after CQ exposure, this may be explained by our prior results of 
no changes in co-localisation between Tau and stable tubulin before or after treatment. Since 
GFP-Tau did not dissociate from stable tubulin and by taking literature into account (Qiang et 
al. 2006; Baas & Qiang 2005), it appears that Tau indeed prevented Katanin 60 from binding 
to the network. Furthermore, where Katanin p60 did appear to co-localise with acetylated α-
tubulin was in the nucleus – confirming Tau’s ability to inhibit Katanin p60 activity because 
pTau, which has reduced binding affinity, also only co-localised with acetylated α-tubulin in 
the nucleus (Fig 3.21). Katanin p60 has also been shown to preferentially be recruited by 
acetylated α-tubulin in vitro in fibroblasts, but the experimental enhancement of α-tubulin 
protein levels in neurons yielded no preferential recruitment or enhanced cleavage of Katanin 
p60 in axons and dendrites rich in Tau (Sudo & Baas 2010). Tau was further shown to inhibit 
Katanin p60 activity when it was overexpressed in the fibroblasts and negated the recruitment 
effect of enhanced acetylated α-tubulin protein levels (Sudo & Baas 2010). 
Furthermore, our findings that Katanin p60 predominantly localises in the nucleus is supported 
by the literature since it has been shown that Katanin p60 plays a critical role in cell division, 
specifically in the process of cytokinesis – the division of cytoplasm – by contributing to the 
controlled microtubule instability occurring during mitosis as well as in the assembly, in 
synergy with Katanin p80, of microtubulin spindle poles (McNally et al. 2000; Matsuo et al. 
2013). Katanin p60 protein levels in neurons is also further developmentally regulated – 
declining with age and spiking during milestones such neurogenesis (Yu et al. 2005). GT1-7 
cells are immortalised hypothalamic neurons which continuously divide and therefore do not 
naturally differentiate. If Katanin p60 protein expression and activity is so closely tied to the 
cell cycle, this would provide an explanation for its predominant nuclear localisation. 
Therefore, for subsequent experiments it would beneficial to assess the effect of CQ-induced 
autophagy dysfunction on terminally differentiated neurons. 
In summary, we report that although CQ-induced autophagy dysfunction caused a progressive 
and significant increase in Katanin p60 protein levels relative to control conditions, it did not 
lead to significant co-localisation between Katanin p60 and stable microtubulin in the cell 
processes, even under control conditions. When interpreting this result in the context of co-
localisation between Tau and stable microtubulin, it suggests that Tau inhibited the ability of 
Katanin p60 to bind to microtubulin even under conditions of enhanced protein levels of 
acetylated α-tubulin, which has been shown to preferentially recruit Katanin p60. 
  





4.6 Summary of findings 
 
 
Figure 4.1: Summary of main findings. CQ induces autophagy dysfunction by inhibiting autophagosome 
degradation. In response to autophagy dysfunction, Tau forms aggregates, but does not dissociate from acetylated 
α-tubulin. Katanin p60 protein levels significantly increase, but it does not associate with acetylated α-tubulin under 
control conditions or during autophagy dysfunction. Spastin increasingly co-localises with acetylated α-tubulin 
during autophagy dysfunction, which is suggestive of enzymatic cleavage. Consequently, the structure of 
acetylated α-tubulin is negatively impacted, manifesting in network breakages and possibly destabilisation. 





Chapter 5: Conclusion 
Alzheimer’s disease is an insidious neurodegenerative disease of the brain which has a highly 
complex aetiology with many underlying molecular mechanisms that remain largely 
uncharacterised. Hallmark characteristics of the disease pathology manifest as the deposition 
of insoluble protein aggregates, which are detrimental to neuronal health (Musiek & Holtzman 
2015). NFTs are composed mainly of hyperphosphorylated Tau, a protein which facilitates the 
dynamic polymerisation and maintenance of microtubule networks. Under homeostatic 
conditions, phosphorylation modulates Tau’s affinity for microtubulin, but in AD Tau is 
hyperphosphorylated causing it to permanently dissociate from the network and aggregate 
into NFTs. Proteolytic processes such as autophagy, which normally aid in the clearance of 
these aggregations, also become dysfunctional during the disease evolution (Nixon & Yang 
2011). Furthermore, Tau dissociation leaves the microtubulin network vulnerable to induced 
destabilisation mediated by the enzymes Katanin p60 and Spastin – leading to deficits in 
axonal transport and contributing to the declining neuronal health (Ahmad et al. 2000; Yu et 
al. 2005; Qiang et al. 2006; Yu et al. 2008; Sudo & Baas 2010; Sudo & Baas 2011). 
The underlying mechanisms that govern Tau hyperphosphorylation, aggregation and 
subsequent microtubulin instability are neither fully understood nor characterized in current 
literature. In addition, it is not known to what extent autophagy dysfunction influences the 
pathological changes associated with microtubule destabilisation, Tau aggregation and 
proteotoxicity. 
Here we report that CQ induces progressive autophagy by inhibiting autophagosome 
degradation (Fig 4.1). The progressive autophagy dysfunction does indeed cause Tau to 
aggregate, but contrastingly causes Tau protein levels to non-significantly decrease. Tau 
phosphorylation does non-significantly increase initially, but Tau located on the network is not 
affected and subsequently does not dissociate. Surprisingly the microtubule network becomes 
more dense and structured over time, but eventually starts destabilising after 24 hours of 
autophagy dysfunction, manifesting in fragmentation. Katanin p60 protein levels increase, but 
this does not lead to increased binding and cleavage of the microtubule network, which is 
likely due the negating effects of the presence of Tau on the network (Fig 5.1A). Spastin 
protein levels non-significantly increase, but progressively and significantly co-localise with 
the acetylated α-tubulin, which suggests that Spastin-mediated cleavage may be the cause of 
microtubulin destabilisation observed after prolonged autophagy dysfunction (Fig 5.1B). This 
further suggests that Spastin’s activity is not affected by the presence of Tau on the 
microtubule network, but is affected by autophagy dysfunction. Our findings further provide 





evidence that autophagy plays a critical role in not only the turnover of Katanin p60, but also 
the microtubulin instability witnessed in AD affected neurons. 
However, and most importantly, we show that these molecular events associated with 
progressive autophagy dysfunction occur prior to the onset of cell death. Therefore, we provide 
not only potentially novel drug targets, but also identify a therapeutic window which highlights 
that treatment interventions should be implemented early in the disease pathogenesis when 
the molecular perturbations are occurring and not at symptom onset, when most of the 
damage has already occurred.  

















Figure 5.1: Potential molecular mechanisms underlying microtubulin instability associated with CQ-
induced autophagy dysfunction. (A) Proposed molecular mechanism underlying changes in Katanin p60 
activity during CQ- induced autophagy dysfunction. (B) Proposed molecular mechanism underlying changes 
in Spastin activity during CQ-induced autophagy dysfunction. 





Chapter 6: Limitations and Future recommendations 
This study has identified previously unknown relationships between progressive autophagy 
dysfunction and microtubulin instability that can be associated with the Alzheimer’s disease 
aetiology. Therefore, replicating our experiment in an in vivo rodent model and confirming our 
in vitro results will strengthen the study as a viable model for Alzheimer’s disease. 
However, to rule out off target effects of chloroquine the study should be replicated in another 
autophagy dysfunctional model such as an Atg5-/- or Atg7-/- knockout in vitro or in vivo model 
or by genetically silencing beclin-1 or Atg5 in GT1-7 cells to render autophagy dysfunctional. 
Furthermore, Aβ-induced Tau pathology can be investigated using an APP overexpression 
model. 
Assessing whether the same changes occur in primary tissue may present a novel diagnostic 
technique for early disease progression. For instance, if the same perturbations in autophagy 
dysfunction induced Spastin-mediated cleavage of the microtubule network are observed in 
non-invasively obtained tissue samples from a suspected Alzheimer’s patient – such as 
fibroblasts from a skin sample – it would provide a novel and non-invasive diagnostic tool for 
Alzheimer’s disease. This would have to entail isolating fibroblasts, back differentiating it into 
induced pluripotent stem cells (IPSCs) and then differentiating into neurons, since the 
microtubule polarity of fibroblasts and neurons are vastly different. 
Furthermore, assessing the protein levels of Spastin and Katanin in post-mortem brain tissue 
of Alzheimer’s disease patients relative to age matched controls may reveal previously 
unknown pathological molecular perturbations in the aetiology of the disease. 
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